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Abstract 
Background 
The impact of early initiation of antiretroviral therapy (ART) on HIV-1 persistence has been 
characterised in adult cohorts and in well-suppressed children on continuous therapy. These 
studies have shown that early ART initiation may limit the size of the latent HIV reservoir that is 
established early in infection. Early initiation of therapy causes a more rapid decay of infected cells 
and may increase the probability of post-treatment control which is valuable for HIV-1 remission 
strategies. However, there remains limited information from longitudinal studies from resource 
limited settings especially investigating the effects of therapy initiation within days of birth on HIV-1 
DNA and viral decay kinetics. Our aims were to investigate total HIV-1 DNA and HIV-1 RNA decay 
in very early treated infants and in older treated children who underwent therapy interruption and to 
determine potential predictors influencing decay.   
Methods  
Participants were selected from two cohorts; eleven infants from a public health sector birth 
diagnosis program who initiated ART at median of four days and 31 children from a clinical trial 
study where children were randomised to elective time-limited therapy or delayed continuous 
therapy. Peripheral blood mononuclear cells (PBMCs) were processed at scheduled study visits 
and plasma viral load measured using commercial diagnostic assays. Following DNA extraction 
from PBMCs, total HIV-1 DNA was quantified using a sensitive real-time PCR assay adapted for 
HIV-1 subtype C targeting a conserved region in the HIV-1 genome (integrase gene). Generalised 
linear and mixed effect regression models; and Spearman rank correlations were used to study 
decay and associating predictors. Statistical tests were implemented in R software version 3.4.3.  
Results 
In our study we observed that infants who initiated therapy at around five days had a faster decay 
rate than children who initiated ART at around five months of age, the half-life (t ½) HIV-1 DNA 
was 2.7 months and 9.2 months, respectively. In the multivariate model, high pre-treatment HIV-1 
DNA level (p<0.001) and an increase in HIV-1 DNA concentration during the period of therapy 
interruption (p<0.01) were independent significant predictors of slower subsequent HIV-1 DNA 
decay. In contrast, children who received prolonged initial treatment for 96 weeks had a faster 
decay after reinitiating on therapy (p=0.02).  
Conclusion 
This study provided some of the first longitudinal data of HIV-1 DNA decay in children from a 
resource limited setting. We suggest early treatment as an important modifiable factor in 
determining HIV-1 DNA decay. Furthermore, we show that very early diagnosis and subsequent 
therapy initiation, when achieving adequate virological suppression, in the early stages of infection 
may be valuable in limiting the persistence of long-lived HIV-1 infected cells.  
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Opsomming 
Agtergrond 
Die impak van vroeë inisiasie van antiretrovirale terapie (ART) op MIV-1-voortbestaan is 
gekenmerk in volwasse kohorte en in goed-onderdrukte kinders tydens volgehoue terapie. Hierdie 
studies het getoon dat vroeë ART-aanvang die grootte van die latente MIV-reservoir wat vroeg in 
infeksie gevestig word, kan beperk. Vroeë terapie aanvang veroorsaak 'n vinniger verval van 
geïnfekteerde selle en kan die waarskynlikheid van na-behandeling beheer, wat waardevol is vir 
MIV-1 remissie strategieë, verhoog. Daar bly egter beperkte inligting van longitudinale studies van 
hulpbronbeperkte instellings, veral om die gevolge van terapieinisiëring binne dae van geboorte op 
MIV-1 DNs en virale vervalkinetika te ondersoek. Ons doelwitte was om die totale MIV-1 DNS en 
MIV-1 RNS verval in baie vroeë behandelde babas en in ouer behandelde kinders wat terapie 
onderbreek het, te ondersoek en om te bepaal die potensiële voorspellers wat die verwal 
beïnvloed. 
Metodes 
Deelnemers is gekies uit twee kohorte; elf babas van 'n geboortediagnose-program vir openbare 
gesondheidsorg wat ART begin het  teen `n mediaan van vier dae en 31 kinders van 'n kliniese 
proefstudie waar kinders gerandomiseer is vir elektiewe tydbeperkende terapie of uitgestelde 
volgehoue terapie. Perifere bloed mononukleêre selle (PBMS's) is geprosesser tydens 
geskeduleerde studiebesoeke en plasma virale lading gemeet met kommersiële diagnostiese 
toetse. Na DNA-ekstraksie van PBMS's, is die totale MIV-1 DNA gekwantifiseer met behulp van 'n 
sensitiewe real-time PKR-bepaling aangepas vir MIV-1 subtipe C wat 'n min-varierende gebied in 
die MIV-1-genoom (integrasegeen) teiken. Algemene lineêre en gemengde effek regressie 
modelle; en Spearman rangkorrelasies is gebruik om verval te bestudeer en voorspellers te 
assosieer. Statistiese toetse is geïmplementeer in R sagteware weergawe 3.4.3. 
Resultate 
In ons studie het ons opgemerk dat babas wat terapie teen ongeveer vier dae begin het, 'n vinniger 
verval gehad het as kinders wat ART teen ongeveer vyf maande begin het. Die MIV-1 DNA 
halfleeftyd (t ½) was onderskeidelik, 2.7 maande en 9.2 maande. In die multivariate model was hoë 
voor-behandeling MIV-1 DNA vlak (p <0.001) en 'n toename in MIV-1 DNA konsentrasie 
gedurende die periode van terapie onderbreking (p <0.01) onafhanklike belangrike voorspellers 
van stadiger daaropvolgende MIV-1 DNA verval. In teenstelling hiermee, het kinders wat 
langdurige aanvanklike behandeling gedurende 96 weke ontvang het, 'n vinniger verval ná terapie 
re-inisiasie (p = 0,02). 
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Gevolgtrekking 
Hierdie studie het van die eerste longitudinale data van MIV-1 DNA-verval in kinders uit 'n hulpbron 
beperkte omgewing gelewer. Ons stel vroeë behandeling as 'n belangrike wysigbare faktor in die 
bepaling van MIV-1 DNA-verval voor. Verder wys ons dat baie vroeë diagnose en die 
daaropvolgende terapie-aanvang met voldoende virale onderdrukking, in die vroeë stadiums van 
infeksie, waardevol kan wees om die voortbestaan langlewende MIV-1-geïnfekteerde selle te 
beperk. 
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Chapter 1: Introduction (Literature Review) 
1.1 The HIV research arena 
The United Nations (UN) member states have pledged their support to end the AIDS epidemic by 
the year 2030. To make this goal achievable the UN has established the 90-90-90 treatment target 
as the major initiative to guide countries towards ending the epidemic in their region.  The 90-90-90 
treatment target stipulates that by the year 2020, of all people infected with HIV 90% should know 
their status, 90% of all HIV infected should be receiving sustained antiretroviral therapy (ART) and 
90% of all receiving ART should reach viral suppression (Joint United Nations Program on 
HIV/AIDS, 2014). Although countries are making steady progress towards achieving this target 
there remains a large proportion of individuals on ART regimens or needing access to ART. 
Lifelong ART comes with many side effects for the patient and it is economically not sustainable for 
health sectors to maintain (Mikkelsen et al., 2017). Therefore developing a cure for HIV remains a 
priority research area. Other research areas such as vaccine development and drug resistance 
remain an important focus in HIV research and ultimately the information generated from different 
disciplines all contribute towards ending the epidemic. This research project aims to contribute to 
knowledge related to HIV-1 persistence and HIV-1 remission (Figure 1.1) with a focus on paediatric 
HIV infection.  
 
Figure 1.1 General overview of the areas of research related to HIV. 
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1.2 Worldwide HIV burden 
The latest global HIV statistics report an estimate of 36.9 million people living with HIV with 21.7 
million having access to antiretroviral therapy (ART). Eastern and Southern Africa remain the 
regions of the world most affected by the HIV pandemic with 19.6 million HIV positive infected 
individuals of which 12.9 million have access to ART (UNAIDS, 2018). South Africa carries the 
largest burden of the disease globally with an estimated 7.2 million infected individuals with a 
prevalence of approximately 12.6% (Statistics South Africa, 2017). Globally there are 
approximately 1.8 million children aged between 0 and 14 years living with HIV, the large majority 
are from Eastern and Southern Africa (an estimated 1.2 million).  
Attempts to reduce HIV transmission through interventions is complicated by the highest burden of 
HIV infections being in resource limited regions. Despite the on-going success of increasing the 
availability of ART to all regions affected by the pandemic, HIV incidence is declining too slowly to 
achieve control (Bekker et al., 2018). Along with the drive to improve access to ART to all infected 
individuals, a focus on implementing primary HIV preventative strategies are needed to accelerate 
the decline in the rate of new infections.  
1.3 Perinatal transmission and Paediatric HIV 
1.3.1 Prevention of mother-to-child HIV-1 transmission  
The majority of paediatric infections occur as a result of mother to child transmission either during 
pregnancy (in utero), during delivery (intrapartum) or through breastfeeding. The rate of 
transmission has been dramatically reduced since the implementation of mother-to-child therapy 
programs (Luzuriaga & Mofenson, 2016). In early trials, such as the Paediatric AIDS Clinical Trials 
Group Protocol 076, researchers investigated the use of a single antiretroviral drug (ARV), 
zidovudine (AZT), given during pregnancy, labour and to the new born as a preventative strategy 
to prevent HIV-1 transmission to the child. The rate of transmission dropped to nearly 70% in 
infants who were not breast-fed (Connor et al., 1994). Further studies assessed the use of two or 
three ARVs and showed an even greater reduction in transmission (Cooper et al., 2002). Based on 
the evidence from these studies prevention of mother-to-child transmission (PMTCT) programs 
have been established in most regions affected by the pandemic. Guidelines have been set by the 
World Health Organisation for the implementation of PMTCT programs and the current 
recommendation is to initiate lifelong ART in all pregnant and breastfeeding women regardless of 
clinical stage or CD4 cell count (WHO, 2015). This option is known as option B+ and is considered 
the most beneficial strategy to prevent transmission in regions with a high HIV prevalence and high 
fertility rates (WHO, 2015). In 2017 approximately 93% of pregnant women in eastern and 
southern Africa where on ARV for the prevention of mother-to-child transmission and a total of 
160,000 new infections were averted as a result of PMTCT programs (UNAIDS, 2018). In a recent 
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study, zidovudine-based ART or tenofovir-based ART had a lower transmission rate than 
zidovudine alone during pregnancy and single-dose nevirapine to the mother and baby. However, 
there were adverse maternal and neonatal outcomes associated with antenatal ART (Fowler et al., 
2017).  Despite the potential risks associated with PMTCT programs, it most importantly has the 
overall benefit of reducing transmission and limiting disease progression and the risk of death in 
perinatally-infected children.  
1.3.2 Characteristics of paediatric HIV-1 infection  
HIV-1 disease progression in children is rapid and associated with a high mortality. In the absence 
of treatment infants frequently have plasma HIV RNA levels greater than 100 000 copies per 
millilitre for months after infection followed by a slow rate of decline reaching set-point at around 
five years of age in children who do not rapidly progress to death (Tobin & Aldrovandi, 2013). In 
contrast, in the absence of treatment adults have a much slower disease progression where AIDS 
or death only occurs at a median of ten years after acute infection. After acute infection the plasma 
HIV RNA level peaks, then it declines (up to a 1000-fold decrease) and a set-point is reached 
within weeks of infection and maintained (Martinez et al., 2016). The immature immune system in 
infants with deficient HIV-1 specific CD4+ T cell responses, ineffective CD8+ T cell responses and 
a delay in antibody-dependent cell-mediated cytotoxicity may contribute to the lack of viraemic 
control observed in children (Martinez et al., 2016; Tobin & Aldrovandi, 2013). Furthermore, 
microbial translocation has also been shown to be a major contributor to infant HIV-1 
pathogenesis. The gastrointestinal tract has a large concentration of CD4+ CCR5+ T cells which 
are highly susceptible to HIV-1 infection (Roider et al.,  2016).  
In the absence of ART HIV-1 disease progression in infants is much faster than in adults. However, 
when children are diagnosed shortly after birth it offers a unique opportunity to treat very early with 
ART. Moreover, the reservoir may be more labile in children with subsequent decay of infected 
cells to low levels as observed in the Mississippi baby and others. Early therapy may also preserve 
immune function which would be valuable for future immunotherapeutic interventions (Goulder et 
al., 2016).  
1.4 HIV-1 Persistence 
1.4.1 HIV-1 integration and latency 
HIV-1 persistence is a result of HIV-1 latency and in order to understand persistence one has to 
understand how latency is established and maintained. One of the characteristic features of all 
retroviruses is the ability to integrate double stranded viral DNA generated by reverse transcription 
of the viral RNA genome, into the host cell DNA (Coffin et al., 1997). These integrated viral 
genomes are referred to as proviruses.  The integration of the viral HIV-1 DNA into the host 
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genome is mediated by the integrase enzyme. Integration takes place at the termini of viral DNA, 
but integration into the host cell DNA can occur at various regions within the genome. Proviral DNA 
is copied when the host cell undergoes cell division and infectious viruses are produced when the 
provirus is transcribed and viral proteins are translated (Craigie & Bushman, 2012). Following 
integration, in some cells HIV-1 can establish a state of latent infection which enables escape from 
host immune surveillance (Siliciano & Greene, 2011). The establishment of the latent viral reservoir 
remains the main obstacle to achieving an HIV cure. How the latent reservoir is established is 
continually being investigated, but figure 1.2 provides an overview of the most likely explanation on 
how the latent reservoir for HIV-1 one is formed and maintained (Sengupta & Siliciano, 2018). 
Upon exposure to HIV-1, activated CD4+ T cells die as a result of the cytopathic effects of the virus 
or host immune responses which result in apoptosis. However, a subset of CD4+ T cells revert 
back to a resting state and HIV-1 gene expression is silenced because it requires the host 
transcription factors to continue the viral replication cycle. HIV-1 remains hidden in these memory 
cells and rapid viral rebound can occur in response to re-exposure to an antigen (Siliciano & 
Greene, 2011).  
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Figure 1.2 The establishment and maintenance of the latent HIV-1 reservoir. (Source: Siliciano & 
Greene,  2011) 
1.4.2 HIV-1 replication and antiretroviral therapy 
As shown in figure 1.3, the first step of the HIV-1 replication cycle is viral entry. HIV-1 fuses with 
the host CD4+ cell surface via recognition of CD4+ receptors and chemokine receptors CCR5 or 
CXCR4. HIV-1 envelope glycoprotein 120 (gp120) binds to CD4 receptor and the co-receptors and 
HIV-1 glycoprotein 41 (gp41) mediates fusion. After fusion with the host cell, HIV-1 RNA is 
converted through a few steps into double stranded DNA, which as pre-integration complex is 
transported across the nucleus and through the catalytic action of the integrase enzyme, it is 
integrated into the host genome, where it exists as a provirus. The host cellular components such 
as transcription factors are used to transcribe new viral RNA from the integrated proviral DNA. The 
new viral RNA contains the necessary information to make new viral proteins to assemble a new 
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virus. The new viral RNA and viral proteins assemble at the cell surface of the host cell to bud off 
and form an immature HIV virion. The protease enzyme initiates proteolysis to cleave viral 
polyproteins to create a mature infectious virion (Arts & Hazuda, 2012).  
 
Figure 1.3 HIV-1 replication cycle (Source: National Institute of Allergy and Infectious Diseases, 
2018. [Online]: https://www.niaid.nih.gov/diseases-conditions/hiv-replication-cycle). 
The understanding of the HIV-1 replication cycle has led to the development of antiretroviral drugs 
that effectively block different stages in the replication cycle. There are six classes of antiretroviral 
drugs that have been developed; nucleoside or nucleotide reverse transcriptase inhibitors (NRTI), 
non-nucleoside reverse transcriptase inhibitors (NNRTI), integrase inhibitors, protease inhibitors, 
fusion inhibitors and co-receptor antagonists (Arts & Hazuda, 2012). Figure 1.4 shows where these 
respective classes of drugs inhibit the HIV-1 replication cycle. Antiretroviral therapy is provided in a 
combination of drugs, which have different mechanisms of action or compete with different 
substrates. Combination ART (cART) effectively blocks new rounds of infection of cells, reducing 
plasma HIV-1 viral load to undetectable levels on commercial assays, which is associated with 
immunological and clinical improvement. Despite the success of ART in limiting disease 
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progression and reversing or preventing immunodeficiency it has no effect on cells already infected 
with HIV and since it does not affect the latent reservoir it is not a cure. Individuals therefore 
require lifelong therapy which comes with challenges such as treatment adherence, drug 
resistance and the large economic burden on health sectors in resource-limited settings. Studies 
focusing on understanding HIV-1 persistence remains a priority research area in attempts to find a 
HIV cure. There are different definitions of cure: whereas the aim of an eradication cure is to rid the 
body of these long-lived HIV reservoirs, a functional cure aims to prevent or control viral rebound 
from reservoir cells in the absence of continued antiretroviral therapy. Considering the difficulty of 
eliminating the latent reservoir, scalable functional cures may be more achievable in the near 
future. 
Figure 1.4 HIV-1 replication cycle and corresponding antiretroviral drug targets. (Source: Arts & 
Hazuda, 2012) 
1.4.3 Markers of persistence and assays used to study HIV-1 persistence 
HIV-1 persistence can be determined through the measurement of different biological markers 
using culture- or PCR-based assays. The true latent reservoir contains replication-competent virus, 
but other forms of HIV-1 DNA and cell-associated RNA have been shown to contribute to HIV 
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pathogenesis and HIV persistence through the formation of viral proteins that can induce immune 
activation or inflammation (Avettand-Fènoël et al., 2016; Rouzioux and Avettand-Fènoël, 2018).  
Measuring replication-competent virus using a viral outgrowth assay (VOA) remains the gold 
standard approach to quantify the true latent reservoir. Resting CD4+ T cells are isolated and 
purified from the patient. The cells are plated at limiting dilutions and phytohemagglutinin (PHA) is 
added along with irradiated peripheral blood mononuclear cells (PBMCs) to induce global T cell 
activation which leads to a reversal of latency and the release of virus (Eriksson et al. 2013; Finzi 
et al., 1997). A p24 antigen detection assay or a reverse transcription-PCR assay are usually used 
to measure the antigen or virus released into the cell culture supernatant after one round of 
stimulation (Bruner et al., 2015). It is important to note that after one round of stimulation only a 
subset of cells are activated. Latency reversal is stochastic and some studies have shown that 
upon another round of stimulation more virus could be recovered (Ho et al., 2013). Therefore, VOA 
underestimates the size of the latent reservoir and may be referred to as the minimal estimate of 
the frequency of latently infected cells. Furthermore, the assay requires a large blood volume, it is 
expensive and labour intensive. However, despite the arduous nature of the assay and the 
underestimation of latent reservoir size, VOA only measures replication-competent virus and 
excludes defective and non-integrated forms of HIV-1 DNA therefore providing the best depiction 
of the true latent reservoir persisting in individuals on suppressive ART.  
PCR-based assays offer high-throughput analysis and they are time and cost-efficient. Many of 
these assays are highly sensitive and require relatively small sample volumes which are suitable 
criteria for paediatric studies. Most PCR-based assays cannot distinguish between replication-
competent virus and defective or non-integrated forms of HIV-1 DNA, but despite this limitation 
these assays provide valuable information about HIV pathogenesis and the overall proviral 
landscape which contain HIV-1 DNA forms that may produce viral proteins that may contribute to 
HIV persistence or the maintenance of cell populations containing replication-competent virus. 
Total HIV-1 DNA is measured using a real-time PCR assay (qPCR) or a droplet digital PCR 
(ddPCR) assay which targets a conserved region in the HIV-1 genome (either HIV-1 gag, pol or the 
LTR region) (Sharaf & Li, 2017). Both assays involve the isolation of PBMCs or CD4+T cells 
followed by extraction of nucleic acid, however, the detection or quantification of total HIV-1 DNA 
differs between these assays. Real-time PCR monitors the reaction in real-time and uses 
fluorescent probes for detection and quantifies total HIV-1 DNA using a standard curve. Droplet-
digital PCR measures endpoint fluorescence and provides an absolute quantification through the 
use of Poisson distribution statistics. As mentioned, these assays cannot distinguish between 
replication-competent virus and defective or non-integrated forms of HIV-1 DNA. An assay that 
addresses this issue is the Alu-gag PCR assay which measures integrated proviral HIV-1 DNA. It 
targets Alu elements which are present in the human genome in high copy numbers and also 
targets an area in the HIV-1 gag gene, (Bruner et al., 2015; Sharaf and Li, 2017). This assay more 
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accurately quantifies HIV-1 integrated DNA if integration occurred in a close proximity to Alu 
sequences in the human genome and a correction factor is used to quantify proviruses integrated 
far from Alu sequences. Despite this limitation, the measurement of integrated HIV-1 DNA is the 
best measurement that correlates with the VOA measurement (Kiselinova et al., 2016).  
In summary, total HIV-1 DNA is a valuable biomarker of the HIV-1 reservoir because it provides an 
overview of all infected cells that may contribute to HIV persistence in patients who are on 
suppressive ART. It may also be predictive of the size of the replication-competent reservoir size in 
ART suppressed patients (Kiselinova et al., 2016). Table 1.1 summarises a few assays used to 
monitor HIV-1 persistence.  
Table 1.1 Assays used to measure HIV-1 persistence 
Assay Measurement  Advantages Disadvantages 
Viral outgrowth 
assay (VOA)  
Measures replication 
competent virus released 
from resting CD4+ T cells 
using reverse transcription 
PCR (RT-PCR) or p24 
antigen ELISA.   
 
 
Quantifies replication-
competent virus 
excluding defective 
proviruses from the 
measurement 
Underestimates latent 
reservoir size  
 
Labour intensive and 
time consuming 
Expensive assay  
Large sample volume 
which is not always 
feasible especially in 
paediatric cohorts 
Real-time PCR 
(qPCR) 
Total HIV-1 DNA including 
defective proviruses and 
unintegrated  HIV-1 DNA 
 
 
The latest assays are 
highly sensitive 
 
It does not distinguish 
between replication 
competent virus and 
defective or 
unintegrated virus 
Different qPCR 
assays target different 
conserved regions 
and measure HIV-1 
DNA relative to a 
standard. Therefore 
the measurement may 
not always be 
comparable to one 
another.  
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Droplet digital 
PCR (ddPCR) 
Total HIV-1 DNA including 
defective proviruses and 
unintegrated HIV-1 DNA 
Provides absolute 
quantification and is a 
more precise 
measurement in 
comparison to qPCR  
It does not distinguish 
between replication 
competent virus and 
defective or 
unintegrated virus 
Alu-gag PCR Integrated proviral HIV-1 
DNA 
Integrated DNA is a 
more comparable 
measurement to VOA  
Limited to detection of 
proviruses close to the 
Alu sequences in the 
human genome 
Detects defective 
proviruses  
 
1.5 HIV-1 Cure strategies 
As mentioned above, the establishment of HIV-1 latent infection in the form of reservoirs remains 
the largest obstacle to achieving a cure. There are two main strategic aims driving HIV-1 cure 
research, namely achieving HIV-1 remission (also known as a functional cure) or achieving 
complete HIV-1 eradication. Regardless of the aim, the effect of latent reservoirs on both strategic 
efforts differ, but remains a challenge to address to attain the goal of a cure.   
1.5.1 HIV-1 eradication  
There are currently only two cases where HIV eradication succeeded: the so-called “Berlin patient”, 
Timothy Ray Brown (Hütter et al., 2009), and the recent London patient (Gupta et al., 2019), both 
had to undergo haematopoietic stem cell transplants for leukaemia and Hodgkin’s lymphoma, 
respectively. Myeloablative therapy (radiation and chemotherapy in case of the Berlin patient and 
chemotherapy alone in the case of the London patient) and graft versus host disease probably 
both contributed to reducing the number of infected cells. However, probably most importantly, 
their clinicians were able to find a matching donor who had the CCR5 delta-32 deletion, which 
provided new blood cells with resistance to HIV. Haematopoietic stem cell transplants without 
providing resistant cells were associated with delayed rebound but no cure and attempts to repeat 
this curative approach with CCR5 delta-32 deletion of autologous cells had not yet been able to 
reproduce a cure, although some preclinical data are promising (Henrich et al. ,2014).  
The most investigated approach to reduce HIV reservoirs is the “shock and kill” strategy. In 
principle it involves the use of latency reversing agents (LRAs) to stimulate latent infected cells to 
release virions after which the immune system is expected to clear virus infected cells through 
immune-mediated cytolysis or apoptosis (Deeks et al., 2016). This is done while the patient is on 
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therapy to prevent new rounds of replication of the virus released from the reservoir. Furthermore, 
in addition to the reversal of latency the immune system must be induced to kill cells infected with 
HIV once they are reactivated, specifically the recognition of infected cells by HIV-1 specific 
cytolytic T lymphocytes (CTLs). However, despite some evidence of latency reversal in a small 
proportion of infected cells, no studies have shown reservoir reduction. There are challenges that 
may prevent CTLs from successfully eliminating reactivated infected cells namely inherent 
resistance to the killing of cells harbouring replication competent HIV (Huang et al., 2018), escape 
mutations in dominant CTL epitopes, LRAs may inhibit CTL function, some reservoirs occur in 
tissues that CTLs are not able to access and exhaustion of HIV-1 specific CTLs which make them 
ineffective in eliminating infected cells (Sengupta & Siliciano, 2018).  Achieving complete 
eradication is a daunting task that requires assays and technology that might not be readily 
available and currently the more feasible strategy towards achieving a cure is achieving HIV-1 
remission.  
1.5.2 HIV-1 remission  
This strategy can be defined as follows: the patient maintains a plasma viral load below limit of 
detection (suppressed) as a result of good immune control, retains normal immune function and 
remains non-infectious, in the absence of ART. This is also commonly referred to as a functional 
cure. There are various studies that have shown promising outcomes towards achieving remission, 
however, in some cases patients have experienced viral rebound after treatment cessation. One 
such study is the case of the Mississippi child who initiated ART within 30 hours of birth for a 
continuous period of 18 months and then discontinued therapy while the viral load remained 
undetectable for a period of more than two years (Persaud  et al., 2013). Subsequently, viral 
rebound occurred in the absence of HIV-specific immune responses  and viraemia reached pre-
therapy levels (Luzuriaga et al., 2015).  Studies including an analytical treatment interruption period 
provide valuable information about virological and immunological factors during the absence of 
ART. In the Viro-Immunologic Sustained Control after Treatment Interruption (VISCONTI) cohort 
14 adults who initiated therapy within primary HIV infection (PHI) for a period 36.5 months all 
maintained a viral load of less than 400 copies per millilitre for a median of 7.4 years after 
interruption (Sáez-Cirión et al.,  2013) these individuals exhibited post-treatment immune control. A 
recent case study of a South African child who received ART at age 61 days and was interrupted 
at 50 weeks of age maintained post-treatment immune control for a period of 9.5 years with 
undetectable plasma HIV-1 RNA and HIV-1 DNA (Violari et al., 2019).  The child presented an 
immune profile similar to uninfected children that included a high CD4:CD8 ratio, low T cell 
activation and low CCR5 expression.  
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1.6 Early diagnosis and early ART initiation 
1.6.1 Impact of early diagnosis 
Early diagnosis of HIV-1 infection enables early initiation of therapy therefore preventing on-going 
replication and the infection of new cells thereby limiting the size of the reservoir that is seeded. 
Furthermore, because of the vulnerability of the infant immune system very early infant diagnosis 
(VEID) and subsequent early therapy initiation leads to a decrease in infant morbidity and mortality 
(Lilian et al., 2013). The Children with HIV early antiretroviral therapy (CHER) randomised trial 
study has shown that initiating ART within 6 to 12 weeks of age can reduce infant mortality by 76% 
and decrease clinical disease progression by 75% (Violari et al.,  2008). VEID may also be seen as 
way to monitor perinatal mother-to-child-transmission rates to ensure that PMTCT programs are 
effective. A recent study has shown that the identification of HIV-1 infection at a later stage 
(median 6 months of age) was associated with higher risk of mortality in infants when compared to 
diagnosis as part of a PMTCT follow-up program (median age 1.6 months of age) (Abrams et al., 
2017). However, it is also important to consider that although rapid diagnosis for infants is 
recommended and available in many clinical settings, follow-up and retention in programs remains 
a challenge for health practitioners. In a recent short report two infants were diagnosed and 
initiated on a triple regimen ART within four hours of life. Despite this rapid response, both patients 
had frequent ARV dose adjustments, treatment adherence issues and eventually one was lost to 
follow-up  (Clarke et al., 2017). For early (or very early) infant diagnosis and early ART programs to 
succeed it requires a considerable effort from HIV clinicians and full support from parents or 
guardians.  
1.6.2 Effects of early ART initiation on HIV-1 Persistence 
Early therapy initiation following early diagnosis plays an important role towards achieving a cure 
for HIV. Early therapy limits the establishment of the latent HIV-1 reservoir and helps to sustain 
immune function which may be essential for immune mediated control, as required for a functional 
cure. Early studies has shown that early ART initiation  results in low levels of markers of HIV 
persistence and undetectable HIV specific immune responses in children who initiated therapy 
before six months of age. At a median age of 6.3 years 60% of children had a low frequency of 
cells harbouring HIV DNA and none had detectable 2-LTR circles (a marker of residual viral 
replication). They also observed high frequencies of CD4+ T cells and low levels of cells 
expressing activation markers (Ananworanich et al., 2014). Another study has shown that infants 
treated before six weeks of age who achieve viral suppression within six months have lower 
frequencies of cells containing replication-competent virus (Persaud et al., 2012). Other evidence 
from adult cohorts has shown that treatment initiated during acute HIV infection (AHI) is important 
in limiting the reservoir size in comparison to adults treated at a later stage  and after 12 months of 
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ART no replication-competent  virus could be detected in patients who initiated therapy before or 
six months after seroconversion  (Strain et al., 2005). A recent cross-sectional study in children 
reported lower levels of HIV-1 DNA in children starting two months of age than those who started 
later (Kuhn et al., 2018). Early therapy also affects the reservoir composition of infected CD4+ T 
cells subsets. Long-term non-progressors have a low infection rate of central memory CD4+ T cells  
and a  larger number of anti-gag  CD8+ T cells (Ananworanich et al., 2015). Similar to what was 
observed in the VISCONTI cohort of post-treatment controllers, central memory CD4+ T cells 
contributed minimally to reservoir composition (Sáez-Cirión et al., 2013). Other studies in adults 
(Martin et al., 2017) and a case study of one child (Violari et al., 2019) have also shown early 
therapy increases the probability of the post-treatment control. Another study aimed to investigate 
the effects of early ART on immune reconstitution in infants and found early treatment limited CD4 
count decline, but did not restore it to levels seen in HIV uninfected infants (Lewis et al., 2017).  
Low HIV-1 DNA levels and smaller latent reservoirs increase the probability of achieving and 
sustaining HIV remission after treatment discontinuation by prolonging viral rebound (Hill et al., 
2014). The Mississippi child initiated therapy within 30 hours of birth for a period of 18 months and 
after discontinuing therapy had a undetectable viral load for two years before viral rebound 
(Luzuriaga et al., 2015) and in an observational study an adult treated with prophylactic ART within 
10 days of infection experienced viral rebound after 7.4 months following analytical treatment 
interruption (Henrich et al.,  2017). However, based on these studies very early ART initiation alone 
does not lead to ART-free remission, but it may delay viral rebound; and by reducing viral diversity 
and sustaining normal immune function, it may provide a good basis towards achieving a functional 
cure.  
1.7 HIV-1 Decay Dynamics  
The rate of decay of HIV-1 infected cells has not been extensively studied in children from 
resource limited settings and the factors that influence the rate of decay have not been fully 
elucidated. From reported studies the influence of the timing of ART initiation plays a significant 
role in HIV-1 DNA and HIV-1 RNA decay dynamics. One study investigated the effects of initiating 
therapy within the primary HIV infection (PHI) phase in comparison to initiation of therapy during 
chronic HIV infection (CHI). The initial decay rate during the first two years of combined ART was 
similar in the two groups, a half-life of 113 days (PHI) and 146 days (CHI).  However, in the second 
phase the half-life of HIV-1 DNA was significantly shorter in the group of individuals treated during 
primary HIV infection, half-life of 25 years in comparison to a half-life of 377 years seen in those 
initiated during CHI. After viral suppression for a median of four years, HIV-1 DNA levels were 
lower in the earlier treated group (Hocqueloux et al., 2013). Despite the similarity in the initial 
decay rate observed in these two groups, these findings suggest that starting ART early plays a 
role in restricting long term survival of infected cells that could inhibit HIV remission strategies. 
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Other studies in adults have also shown that initiation of therapy during acute HIV infection results 
in a much faster initial decline in HIV-1 DNA levels and HIV-1 DNA set point is rapidly reached 
(Ananworanich et al., 2016; Laanani et al., 2015).  
In children a similar trend is seen, but the decay rate observed is much faster in comparison to 
adults. In children initiating ART within 2.6 months of age the HIV-1 DNA concentration decayed to 
as low as 1.0 log copies per million cells after two years (Luzuriaga et al., 2014) and in children 
who initiated around a median of two months of age the median half-life was 53 days (Uprety et al., 
2015) and in children who initiated ART before three months of age the half-life was 107 days 
(McManus et al., 2016). These findings further support the role of initiating ART as soon as 
possible following infection to ensure rapid decay of HIV-1 infected cells. Thereby limiting the size 
of the latent reservoir that may be established.  
1.8 Rationale  
1.8.1 Summary of Literature review  
The global effort to increase access to antiretroviral therapy has reduced mortality rates among 
HIV-1 infected individuals, it has prevented more transmission events and has increased life 
expectancy among HIV positive individuals. However, the sustainability of life-long ART is 
threatened by the cost, side effects of long term usage and the potential accumulation of drug 
resistance mutations. Research continues towards finding a functional cure that will allow patients 
to discontinue therapy and remain virologically suppressed and maintain good immune control 
without ART. The major barriers to achieving this is the early establishment of a persistent latent 
reservoir of infected memory CD4+ T  cells and the inability of most patient immune responses to 
control replication and prevent immune function decline. In the majority of patients, upon treatment 
cessation HIV-1 reservoirs stochastically reactivate from a latent state and virus replication 
continues.  
The impact of very early treatment on the long-term survival of infected cells requires further 
investigation. The majority of reported studies have focused on adult cohorts and there remains a 
gap to provide information related to paediatric cohorts especially from resource limited settings. 
Furthermore, there are few reports providing longitudinal data for HIV-1 DNA and HIV RNA kinetics 
in children and associating clinical factors influencing the decay of infected cells.  
1.8.2 Research questions  
Our study aims to address the following research questions. 
i. Is there a significant difference in the decay rate seen in infants treated within days after 
birth versus children who are treated weeks or months later? 
ii. What factors influence HIV-1 DNA and HIV-1 RNA decay in children? 
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1.8.3 Aims and Objectives  
This is a descriptive longitudinal study that aims to describe HIV-1 DNA and HIV-1 RNA decay in 
children and determine what factors could be influencing decay. Figure 1.5 gives an overview of 
the aims and objectives that have been set for this research project to answer the above 
mentioned research questions.  
Figure 1.5 Overview of the aims and objectives for this research project.  
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Chapter 2: Materials and Methods 
2.1 Ethical considerations 
This research project falls under a larger study which was granted ethical approval by the Health 
Research Ethics Committee of Stellenbosch University, South Africa. Approval was granted on the 
20 September 2017 with the following ethics reference number, M14/07/029.  
2.2 Study specific definitions 
2.2.1 Total HIV-1 DNA and plasma HIV-1 RNA 
In this study total HIV-1 DNA refers to the total HIV-1 cell associated DNA in peripheral blood 
mononuclear cells that have been extracted from whole blood. Total HIV-1 DNA was measured 
using a real-time PCR assay targeting the integrase gene. Plasma HIV-1 RNA refers to the free 
plasma HIV-1 RNA load measured in the plasma using commercial diagnostic assays.  
2.2.2 Total HIV-1 DNA decay   
HIV-1 DNA decay refers to the change in total HIV-1 DNA (an estimate of the total number of 
infected cells) over time (Josefsson et al., 2011). To perform linear regression total HIV-1 DNA was 
log transformed to study the decay of HIV infected cells over time.  
2.2.3 Predictor 
For the purpose of this study predictors are clinical or laboratory measurements that may explain 
or predict differences in HIV-1 DNA levels or rate of change of HIV-1 DNA when included in a 
statistical model. If predictors reach statistical significance and independently predict an outcome 
in a multivariate model it does not imply that they are the cause of the outcome, but merely that the 
association is statistically significant.  
2.2.4 Continued treatment  
Refers to the phase of therapy since treatment initiation in therapy uninterrupted patients or since 
therapy re-initiation in therapy interrupted patients. 
2.3 Study design and participants 
This research project aimed to investigate total HIV-1 DNA kinetics and plasma HIV-1 RNA kinetics 
in two different cohorts. Predictors associated with decay kinetics were only studied in one of the 
cohorts due to readily available clinical data. Below is a schematic giving an overview of the steps 
employed in this project to achieve the aims and objectives of this study.  
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Figure 2.1 Schematic of overall study design 
Cohorts studied and participant selection criteria 
2.3.1 Very early infant diagnosis (VEID) cohort:  
Infants were diagnosed as part of a public health sector birth HIV-1 diagnosis program in Cape 
Town, South Africa. To confirm HIV-1 infection at least two positive HIV-1 nucleic acid test results 
on two separate samples were needed. A quantitative, COBAS® AmpliPrep/COBAS® TaqMan® 
(CAP/CTM) HIV-1 version 2.0 or HIV-1 Qualitative version 2.0 (CAP/CTM) (Roche Molecular 
Diagnostics, Pleasanton, CA) tests were used. Following confirmation of test results, children were 
enrolled into an HIV-1 reservoir and neurodevelopment study. For the purpose of this Master’s 
project a subset of 11 were studied (inclusion criteria below). All children were part of a Prevention 
of mother-to-child transmission (PMTCT) program that consisted mainly of a dual regimen of 
nevaripine (NVP) and zidovudine (AZT), replaced by triple combination therapy once diagnosed as 
HIV positive, whereas some children diagnosed at birth were immediately initiated on triple 
combination therapy (consisting of AZT, 3TC (lamivudine) and NVP) as described in Table 2.1. 
Nevaripine was replaced by lopinavir-ritonavir (LPV/r) at corrected age of 42 weeks and AZT 
replaced by ABC (abacavir) at approximately 3 months of age. Clinical visits and viral loads tests 
were done every 3 months. Plasma HIV-1 RNA was quantified with the Roche (CAP/CTM) version 
2.0, with a 100 copies per millilitre limit of detection for a 200 microliter plasma input.  
2.3.2 Children with HIV early antiretroviral (CHER) randomised trial cohort and Post-CHER cohort 
The CHER study was a clinical trial conducted in two locations in South Africa; in Johannesburg at 
the HIV Research Unit, Chris Hani Baragwanath and in Cape Town at the Children’s Infectious 
Sample selection 
and processing 
•  Set up criteria to select suitable samples 
•  Perform peripheral blood mononuclear cell 
isolation from whole blood samples  
Quantifying total 
HIV-1 DNA 
•  DNA extraction from stored sample cells 
•  DNA extraction from dried blood spots where 
baseline PBMCs were not available 
•  Employ a senstive real-time PCR assay to 
quantify total cell associated HIV-1 DNA  
Statistical 
analyses 
 
•  Analyse decay kinetics 
•  Determine potential predictors of 
decay using correlation tests or mixed 
effect regression models 
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Diseases Clinical Research Unit, Tygerberg Hospital (Cotton et al., 2013; Violari et al., 2008). 
Infants were recruited into the study following confirmation of HIV infection by a positive PCR test 
for HIV-1 DNA. Other entry criteria were a plasma HIV-1 RNA PCR test result of greater than 1000 
copies per millilitre. Children with a CD4 percentage of 25% or more formed part of the main trial 
(Part A) whereas children with a CD4 percentage below 25% were assigned as Part B (and were 
excluded from the primary analysis which compared immediate to deferred therapy). Following 
recruitment into the study participants from Part A were randomised into three arms defined by 
three different treatment strategies and Part B participants were only randomised into two of the 
three arms (excluding the deferred arm as they required immediate therapy). The arms are as 
follows: 
 Arm 1: Deferred ART therapy. Children were not started immediately on therapy. 
 Arm 2: Early time limited therapy for 40 weeks. Children received therapy for 40 weeks and 
subsequently therapy was interrupted. 
 Arm 3: Early time limited therapy for 96 weeks. Children received therapy for 96 weeks and 
subsequently therapy was interrupted. 
Within each arm the following immunological criteria were used either to initiate therapy in Arm 1 
(delayed therapy arm) or re-initiate therapy in Arm 2 or Arm 3: A CD4 percentage of less than 20% 
or in the case of infants younger than 12 months a CD4 percentage less than 25% or a CD4 count 
of less than 1000 cells per cubic millimetre. Participants were started on a first line ART regimen 
that consisted of zidovudine (AZT) and lamivudine (3TC) with lopinavir-ritonavir (LPV/r). The 
second line regimen consisted of didanosine (DDI), abacavir (ABC) and, and nevaripine (NVP) or 
efavirenz (EFV). Following the conclusion of the clinical trial a subset of children were retained in 
post-CHER descriptive studies to investigate neurocognitive outcomes and HIV-1 reservoirs. The 
participants for this Master’s project were selected from the Cape Town site, who were retained in 
post-CHER follow up studies. Clinical assessments (such as monitoring CD4 counts) and viral load 
tests were done at regular study visits. We selected participants based on specific criteria listed 
below and Table 2.2 summarises the patients included in this project. .  
2.3.3 Participant inclusion criteria 
To answer the research questions set out in this study the following criteria were set to select 
participants from the above mentioned cohorts. 
I. VEID cohort 
Participants were selected if: 
 The individual initiated ART within eight days of birth. 
 The individual had a detectable total HIV-1 DNA baseline sample available. 
 There were two stored PBMC samples available while on treatment. 
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II. CHER and Post-CHER cohort  
Participants were selected if: 
 The individual had a baseline sample before therapy initiation if the patient was on 
continuous therapy (CHER Arm 1).  
 The individual had a baseline sample before therapy re-initiation if the patient was 
subjected to therapy interruption (CHER Arm 2 or Arm 3). 
 Participants had two early time points and at least 1 late time point (Post-CHER 
sample). 
 
Table 2.1 Participants selected from the VEID cohort. “S” indicates virologic suppressed infants 
and “V” viraemic infants. Virologic suppression was defined as a continuous downward trend in 
plasma HIV-1 RNA and a HIV-1 RNA load <100 copies/mL after 6 months on ART. Participants not 
meeting these criteria were classified as viraemic.  
Patient ID  Gender  Child 
PMTCT  
Child PMTCT 
Drugs  
Age(days) at 
ARV Start #  
Age (days) 
recruited*  
S2  Male  Yes  Immediate cART  0  35  
S3  Female  Yes  NVP, AZT  3  18  
S4  Female  Yes  AZT/3TC  5#  7  
S5  Male  Yes  NVP, AZT  7  22  
S6  Female  Yes  Immediate cART  0  30  
S7  Female  Yes  NVP, AZT  6  12  
S9  Male  Yes  NVP, AZT  8  8  
V1  Female  Yes  NVP  6  22  
V3  Male  Yes  NVP, AZT  8  54  
V4  Male  Yes  NVP, AZT  7  20  
V5  Female  Yes  NVP, AZT  4  10  
# A 2-5 day delay between initial dual therapy and triple therapy. The initial combination antiretroviral regimen in all was 
azidothymidine (AZT), lamivudine (3TC) and nevirapine (NVP). NVP was replaced by lopinavir/ritonavir (LPV/r) at a 
corrected age of 42 weeks; AZT was replaced by abacavir (ABC) at approximately 3 months of age. *On the recruitment 
day the first PBMC samples to investigate HIV-1 reservoirs were collected. 
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Table 2.2 Participants selected from the CHER/Post-CHER cohort. 
CHER 
Treatment 
Strategy 
Patient ID Gender Age at initiation 
(days) 
Initial ART regimen 
Part A Arm 
1 
330812 Female 256 AZT, 3TC, LPV/r 
335366 Female 135 AZT, 3TC, LPV/r 
335726 Female 139 AZT, 3TC, LPV/r 
336926 Male 290 AZT, 3TC, LPV/r 
339606 Male 259 AZT, 3TC, LPV/r 
338956 Female 174 AZT, 3TC, LPV/r 
330446 Female 450 AZT, 3TC, LPV/r 
331976 Female 129 AZT, 3TC, LPV/r 
Part A Arm 
2 
339316 Male 51 AZT, 3TC, LPV/r 
333676 Female 51 AZT, 3TC, LPV 
336306 Female 51 AZT, 3TC, LPV/r 
337756 Female 70 AZT, 3TC, LPV/r 
338346 Female 49 AZT, 3TC, LPV/r 
338796 Female 64 AZT,3TC,  LPV/r 
339046 Male 51 AZT, 3TC, LPV/r 
339486 Male 52 AZT, 3TC, LPV/r 
339736 Female 65 --- 
340206 Female 50 AZT, 3TC, LPV/r 
341622 Male 64 AZT, 3TC, LPV/r 
145046 Male 41 AZT, 3TC, LPV/r 
330636 Male 52 AZT, 3TC, LPV/r 
335496 Female 58 AZT, 3TC, LPV/r 
331232 Female 84 AZT, 3TC, LPV/r 
331766 Female 54 AZT, 3TC, LPV/r 
332196 Male 65 AZT, 3TC, LPV/r 
333946 Male 55 AZT, 3TC, LPV/r 
Part A Arm 
3 
340566 Male 60 AZT, 3TC, LPV/r 
339156 Male 53 AZT, 3TC, LPV/r 
333716 Female 70 AZT, 3TC, LPV/r 
336456 Female 64 --- 
330556 Female 49 AZT, 3TC, LPV/r 
341286 Male 55 AZT, 3TC, LPV/r 
331122 Male 82 --- 
331596 Female 46 AZT, 3TC, LPV/r 
333226 Female 68 AZT, 3TC, LPV/r 
338686 Male 54 AZT, 3TC, LPV/r 
Part B Arm 
2 
360672 Male 68 AZT, 3TC, LPV/r 
360132 Female 50 AZT, 3TC, LPV/r 
360392 Male 79 AZT, 3TC, LPV/r 
360712 Male 84 AZT, 3TC, LPV/r 
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2.4 Peripheral blood mononuclear cell (PBMC) isolation 
This protocol was performed in a Biosafety level 2 laboratory. Whole blood (EDTA) samples were 
received from participants and transferred to a Falcon tube (either 15 mL or 50 mL depending on 
the sample volume). The samples were then centrifuged (Rotanta 460 R, Hettich, USA) at 967 x g 
for ten minutes with the  brake and acceleration step set to the highest level on the centrifuge. This 
step separates plasma from other whole blood components such as white blood cells, red blood 
cells and platelets. Following centrifugation the plasma supernatant was removed and stored at -
80⁰C for other assays. The remaining cells were re-suspended with an equal amount of 1X 
phosphate-buffered saline (PBS) (Lonza, Switzerland) in relation to the amount of plasma 
removed. The reconstituted blood was layered onto a density gradient cell separation medium 
called Histopaque Ficoll (Sigma-Aldrich, USA). For large blood volumes approximately 15 mL of 
media was used and for smaller blood volumes between 5-6 mL of Ficoll was used.   
After layering the blood on the separation media the samples were centrifuged for 30 minutes at 
434 x g (with the brake and acceleration step removed or set to the lowest level).  After the 
centrifugation step the presence of four layers was evident and the buffy white coat containing the 
PBMCs was removed by extending a bulb pipette through the above layer and carefully extracting 
the cells. The cells of each sample were transferred to an empty Falcon tube (15 mL or 50 mL 
depending on initial blood volume size) and 1X PBS was added to fill up each tube to maximum 
capacity. The cells were centrifuged at 278 x g for 17 minutes (with the brake and acceleration step 
removed or set to the lowest level). After this wash step the PBS was carefully decanted and the 
pellet was re-suspended in the excess PBS left in the tube. If the initial sample volume was above 
20 mL, then the wash step was repeated by filling up the tube with 1X PBS and centrifuging the 
tubes again. For smaller initial blood volumes, 1-5 mL of 1X PBS was added to the reconstituted 
pellet after the first wash step in preparation for cell counting. After the second wash of the larger 
blood volume, the PBS was again decanted and the cell pellet re-suspended in the excess PBS. 
For cell counting, 20 mL of 1X PBS was added to the reconstituted pellet and Trypan Blue (Bio-
Rad Laboratories, USA) was used to stain the cells to count the cells using a TC20™ Automated 
cell counter (Bio-Rad Laboratories, USA).  
Fifty microlitres of Trypan Blue was mixed with 50 µL of cells and then 10 µL of this mixture was 
pipetted onto both sides of a counter slide (side A and side B). The outside of the slide was wiped 
with 70% ethanol and then placed into the cell counter. The lower gate was set to 6 µM and the 
upper gate set to 17 µM. A total of four counts were read (two on each of the slide) and the 
average cell count was used in further calculations to determine the amount of cryopreservation 
media needed (Addendum A1). The cells were then centrifuged at 275 x g for ten minutes and the 
media prepared using dimethyl sulfoxide (DMSO) and fetal bovine serum (FBS).After 
centrifugation, the PBS was decanted and the pellet reconstituted in the remaining PBS and then 
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the cryopreservation media was added to the cells in a drop wise manner while swirling the tube to 
ensure that the cells were evenly mixed into the media. Then 1 mL aliquots of 2.5 million cells were 
stored in a Mr Frosty overnight at -80˚C and then transferred to liquid nitrogen for long term 
storage.  
2.5 DNA extraction from peripheral blood mononuclear cells (PBMCs) 
This protocol was performed in a Biosafety level 2 laboratory. Samples were removed from liquid 
nitrogen and placed at -80˚C overnight to equilibrate before carrying on with the extraction 
protocol. The following day and prior to removing samples from -80˚C the dry baths (AccuBlock™, 
Labnet International, USA) were set to 37˚C and 42˚C, respectively. Samples were then removed 
from -80˚C and placed on dry ice. During this time, the Roswell Park Memorial Institute (RPMI) 
media was heated at 37˚C for approximately ten minutes (1 mL of media per sample). Following 
this the samples were placed at 37˚C for approximately two minutes (one sample at a time). 
Samples thaw at different rates and must not be left unattended to ensure cells are not destroyed. 
After the samples were thawed, 1 mL of RPMI media was added drop-wise to each sample. 
Samples were stored at various cell concentrations, for the purpose of this study we only aimed to 
extract from 800 000 to 1 000 000 cells so that we extract a sufficient amount of DNA, but also not 
too much that it inhibits downstream assays (i.e. the real time PCR assay). Therefore, after adding 
RPMI media to each sample the cells were split into pre-calculated volumes to ensure that we only 
extracted from within the range of the cell concentrations mentioned above. The split sample 
volumes are transferred from the cryovials to 1.5 mL tubes and centrifuged (Prism R, Labnet 
International, USA) at 500 x g for five minutes. The supernatant was carefully removed and the cell 
pellets were stored on dry ice until all individual samples have undergone the above steps. The 
remaining protocol was carried on with one aliquot of cell pellet and the rest of the cell pellets were 
stored at -80⁰C.  
Thereafter, 100 µL of a Guanidinium Hydrochloride (GuHCl, 8 M, Sigma-Aldrich, USA) and 
Proteinase K (20 mg/mL, ABI Scientific, USA) solution is prepared for each sample by adding 50 
µL of Proteinase K per 1 mL of GuHCl+/ProK required (Addendum A2). Once the solution was 
made a 100 µL was added to each cell pellet and immediately sonicated (Omni Sonic Ruptor 400, 
Omni International, USA) for 10 seconds. If the cell pellet had not completely dispersed it was 
further sonicated for another five seconds. Following this the samples were placed at 42⁰C for one 
hour. During the incubation step 400 µL of Guanidinium Isothiocyanate (GuSCN, 6 M, Sigma-
Aldrich, USA) and glycogen (Gly, 20 mg/mL, ABI Scientific, USA) solution was prepared for each 
sample by adding 30 µL of glycogen per milliter L of GuSCN+/Gly required (Addendum A2). After 
the incubation step samples were removed from the dry bath and 400µL of GuSCN+/Gly were 
added to each sample. Each sample was vortexed for 10 seconds and placed back on the dry bath 
for a further 10 minutes. Then 500 µL of 100% isopropanol (at room temperature) was added to 
Stellenbosch University https://scholar.sun.ac.za
23 
 
each sample and vortexed for 10 seconds at a high intensity and centrifuged for 10 minutes at 
21 000 x g to pellet the nucleic acid.  
The supernatant was then carefully removed and 750 µL of 70% ethanol (at room temperature) 
was added to each sample. The samples were then vortexed for 10 seconds and centrifuged for 10 
minutes. After this wash step the supernatant was removed and the samples spun at 21 000 x g for 
15 seconds. After this quick centrifugation step any residual ethanol was removed and the pellets 
were air dried by keeping the tubes open until the pellet appears semi-translucent. It took 
approximately 3-7 minutes to dry and had to be carefully monitored to prevent the pellets from over 
drying which may make it difficult to re-suspend the pellet. After the pellet had dried, 70 µL of 5 mM 
Tris-HCl (diluted from stock: 1 M Tris-HCl, pH 8.0, Sigma, USA) was added to each sample. The 
samples were sonicated for 10 seconds at 60% amplitude to properly dissolve the nucleic acid into 
solution. The extracted DNA was stored at -80⁰C until needed for other assays.  
2.6 Adapted method for DNA extraction from a dried blood spot (DBS) 
2.6.1 DNA extraction from DBS 
This protocol was performed in a Biosafety level 2 area. The same DNA extraction method in 
section 2.5 was adapted for the extraction of nucleic acids from dried blood spots. Figure 2.2 
provides a brief overview of this method particularly highlighting the main amendments made to the 
existing method. Firstly, the amount of lysis solution used was increased and samples were stored 
overnight at 37⁰C in this solution.  
Figure 2.2 Overview of nucleic acid extraction from a dried blood spot (DBS).  
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For each sample one dried blood spot was punched out and placed in a 1.5 mL tube. A lysis 
solution consisting of Guanidinium hydrochloride and Proteinase K was prepared. Six hundred 
microlitres of the lysis solution was needed for each sample and the total volume was calculated 
according to formula in the addendum A2. The lysis solution was added to the sample and the 
sample was immediately sonicated for ten seconds at 60% amplitude. The samples were 
incubated overnight at 37⁰C on a dry bath. The next day a Guanidinium isothiocyanate and 
glycogen solution was prepared (Addendum A2). The sample was taken off the heating block and 
in three new 1.5 mL tubes the total sample volume was split into three volumes consisting of 200 
µL each. Four hundred microlitres of the GuSCN/+Gly solution was added to the samples and 
vortexed for 10 seconds. The samples were placed on the heating block for a further 10 minutes. 
Following this step 500µL of 100% isopropanol (stored at room temperature) was added to each 
sample and vortexed at a high intensity for 10 seconds. Samples were transferred to a centrifuge 
and spun at 21 000 x g for 10 minutes. The supernatant was removed and the pellet (consisting of 
the nucleic acid) was washed using 750 µL of 70% ethanol and vortexed for 10 seconds. Samples 
were stored overnight at -20˚C to properly wash the pellet and sufficiently dissolve any possible 
contaminants. The next day samples were spun at 21 000 x g for 10 minutes and the supernatant 
removed and then again spun for 15 seconds at 21 000 x g to remove any excess supernatant. 
The samples were dried on the bench top until the pellet was semi-translucent. Each dried pellet 
was re-suspended with 23.33 µL 5  mM Tris-HCl and stored overnight at -20˚C to allow the nucleic 
acid to properly dissolve into solution. Each sample that was initially split into three at the 
beginning of the protocol was pooled into one tube with a total volume of 70 µL and the DNA 
concentration and purity was determined using a spectrophotometer (NanoDrop 1000, Thermo 
Fisher Scientific, USA). 
2.6.2 Determining the total amount of peripheral blood mononuclear cells in a dried blood spot  
There were no baseline PBMC samples available for the VEID cohort therefore we sourced 
baseline dried blood spots as way to overcome this limitation. However, the DNA extraction 
protocol (described in Section 2.5) had to be amended to enable extraction of nucleic acids from a 
dried blood spot. In our standard protocol we extracted from PBMC samples which in comparison 
to DBS is a more pure sample containing mainly lymphocytes. DBS is a whole blood sample 
containing other cells such as granulocytes in addition to lymphocytes. To determine the amount of 
lymphocytes that were present in a dried blood spot the following experiment was set up. We 
obtained residual NHLS infant samples that tested HIV negative at approximately the same age as 
expected for positive baseline samples (between the ages of one to eight days old). A blood 
volume of at least 250 µL was needed to have enough blood to make a 50 µL dried blood spot and 
peripheral blood mononuclear cells were extracted from the remaining blood. The amount of 
samples available for selection was limited due to insufficient blood volumes below 250 µL and 
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other stored samples were haemolysed and not suitable for use in this experiment. Subsequently 
only two HIV negative samples were obtained, sample one (named Neg 1) had a blood volume of 
250 µL and sample two (named Neg 2) had a blood volume of 300 µL. For each sample a dried 
blood spot was made on a Guthrie card and from the same sample PBMCs were isolated from the 
remaining blood according to the same method in section 2.4.  DNA was extracted from the dried 
blood spot using the method in section 2.6.1 and DNA was extracted from the EDTA whole blood 
PBMC samples according to the method in section 2.5. A real time PCR assay was used to 
determine the amount of cells assayed by quantifying the total number of copies of CCR5 in each 
sample. The real-time PCR assay used is described in detail in section 2.7.2. Thereafter the total 
number of cells recovered from a dried blood spot (which would include polymorphonuclear cells) 
was expressed in relation to the number of peripheral blood mononuclear cells recovered from the 
same volume of processed whole blood.  
2.7 Integrase cell associated total HIV-1 DNA assay (iCAD) 
2.7.1 Preparation of integrase HIV-1 Subtype C DNA integrase standard for iCAD 
A set of primers (Addendum A3) designed to amplify a 418 bp fragment from the HIV-1 subtype C 
integrase gene was used to generate amplicons from the pMJ4 plasmid (HIV-1 subtype C clone). 
The following master mix concentrations were used to prepare a master mix for 20 reactions 
(Table 2.3). We selected 20 reactions as a start to have enough product downstream especially 
after purification. The master mix was added to 20 PCR tubes and 5 µL of pMJ4 linearized plasmid 
was added to each tube. The reactions were run on a thermocycler (9700 PCR System, Applied 
Biosystems, USA) with the following cycle parameters listed below (Table 2.4). The products were 
run for 45 minutes at 90 volts on a 0.8% agarose gel alongside a 1  kb DNA ladder to determine if 
the reaction worked and the correct band size of 418  bp was observed. Nine microliters of loading 
dye and 45 µL of each product were mixed separately and loaded onto a gel containing EZ 
Vision® (VWR International. USA). The gel was viewed using the UVITEC Cambridge Gel Doc 
system.  
Table 2.3 Master Mix calculations to generate 418  bp amplicon containing HIV-1 subtype C 
integrase insert 
Reagent Stock Concentration  Final 
Concentration  
Volume per reaction 
(µL) 
PCR grade H2O -- -- 25.75 
GoTaq Buffer 5X 1X 10 
dNTPs 40 mM  1.25 mM  1 
MgCl2 25 mM 2 mM 4 
P1 10 µM 0.4 µM 2 
P2 10 µM 0.4 µM 2 
GoTaq Enzyme 5 U/Ul 1.25 U 0.25 
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DNA 2 ng/µL 10 ng 5 
Total -- -- 50 
 
Table 2.4 Cycling parameters for endpoint PCR.  
Step Temperature Time 
Initial denaturation 94°C 2  min 
Denaturation 94°C 30  s 
Annealing 44°C  30  s                 30 cycles 
Extension 72°C 30  s 
Final extension 72°C 7  min 
Hold 4°C ∞ 
 
The 418 bp amplicon was gel extracted using the Qiaquick gel extraction kit (Qiagen, Netherlands) 
according to the manufacturer’s instructions. Following gel extraction ethanol precipitation was 
performed to purify the sample from any salts carried over into the sample during extraction. The 
following steps were carried out: 3  M Sodium acetate equivalent to a tenth of the extracted DNA 
volume was added to the tube containing the DNA (for example if the extracted DNA volume is 200 
µL then 20 µL of Sodium acetate was added). In addition to this, 100% ice cold ethanol was added 
to each tube. The amount of ethanol was equivalent to 3 times the volume of extracted DNA. The 
solution was thoroughly mixed using a vortex and then placed at -20⁰C overnight to precipitate. 
The next day the tubes were centrifuged at 17000 x g for 30 minutes. The pellet was washed using 
500 µL ice cold 80% ethanol and centrifuged for 10 minutes. The wash step was repeated and the 
ethanol was removed. The tubes were centrifuged at full speed for 10 seconds to remove any 
residual ethanol and the pellet air dried. Once dried the pellet was re-suspended in 200µL 5 mM 
Tris and thoroughly mixed using a vortex. The sample purity was determined using a NanoDrop 
1000 and then 5 µL of product with  1 µL Novel juice (GeneDirex, USA) was run on a 1% gel with a 
1 kb DNA ladder for 45 minutes at 90  V to ensure that the correct fragment size was gel extracted 
and purified. The DNA concentration was quantified using a Qubit® 2.0 fluorometer (Thermo 
Fisher Scientific, USA) with the Qubit® dsDNA HS Assay kit instructions provided by the 
manufacturer. The concentration, amplicon sequence and base pair length were used to calculate 
the exact DNA copy number using an Endemo DNA Copy number calculator available online 
(Addendum  A4).  After determining the DNA copy number ten-fold serial dilutions were performed. 
First the initial DNA copy number was diluted to 1 x1010  copies/µL and then ten-fold serial dilutions 
were performed down to a concentration of 1 x105 copies/µL. Serial dilutions were done using the 
following method: 900 µL of 5 mM Tris was dispensed into five 1.5 mL tubes and 100 µL of the 1  
x1010 copies/µL (standard stock) was transferred into the first 1.5 mL tube labelled 1 x109. To mix 
the solution the tube was inverted 30 times and then incubated at 56⁰C for five minutes. The tube 
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was then placed on wet ice for one minute and for each subsequent solution 100 µL of the solution 
was dispensed from the previous dilution into the next tube and diluted following the same method 
down to 1  x105 copies/µL. Figure 2.3 shows an overview of the above mentioned serial dilution. 
Single-use aliquots were made of the 1  x105 copies/µL HIV-1 subtype C integrase standard. 
 
 
Figure 2.3 Basic overview of the method used to dilute HIV- 1 integrase standard 
2.7.2 Limiting Dilution experiment to verify HIV-1 Integrase standard 
A real time PCR limiting dilution assay was used to verify if the HIV-1 DNA integrase standard 
generated was at the correct concentration of 1 x105 copies/µL. A master mix for 96 reactions was 
prepared according to Table 2.5 (primers and probe are listed in the Addenda) and while on a 
cooling block, 15 µL of the master mix was dispensed into each well of a 96-well real time PCR 
plate (Bio-Rad Laboratories, USA). The plate was covered with an aluminium cover to prevent 
probe exposure to light and the standard which was prepared as in section 3.7.1 was diluted from 
1  x105  copies/µL down to one copy per well (10 µL). Figure 2.4 shows the overall method used to 
perform the serial dilution, 108 µL of 5 mM Tris was dispensed into twelve tubes and 50 µL of the 
HIV-1 DNA integrase standard was transferred to the first tube labelled 3 x105 copies/10 µL and 
the pipette tip was changed before mixing 15 times by aspirating and dispensing using the 
micropipette. Subsequently to that, 50 µL of this new dilution was transferred to the next tube 
labelled 1 x105 copies/10µL and the process was repeated until 1 copy/10 µL was reached. The 
dilutions performed are a 1 to 3.2 dilution because 3.2 ≈ (is almost equal to) 101/2 therefore every 
second dilution in the series is a ten-fold dilution. After completing the serial dilution, 10 µL of each 
dilution from 3000 copies/10 µL to one copy/10 µL were dispensed in replicates of 10 according to 
the plate layout in Figure 2.5. The plate was tightly sealed with clear plastic film and placed on a 
CFX Connect real-time PCR machine (Bio-Rad Laboratories, USA) and the following cycle 
conditions were used: Step 1: 95⁰C for five minutes, Step 2: 95⁰C for 15 seconds, Step 3: 60⁰C for 
one minute and then step 2-3 is repeated for 50 cycles and then a final hold step at 37⁰C was set. 
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After completion of the run the results were analysed using Bio-Rad CFX Manager version 3.0 
software.  
 
Figure 2.4 Basic overview of method used to perform dilution series.  
 
 
Figure 2.5 Plate layout for limiting dilution assay 
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2.7.3 Real-time PCR assay 
An in-house real time PCR assay was used to quantify total HIV-1 DNA in peripheral blood 
mononuclear cells and dried blood spots. This assay was developed by our research collaborators 
and adapted to target the integrase gene in HIV-1 subtype C (Hong et al., 2016) . This is an 
ultrasensitive assay with a limit of detection of 3 copies per million cells. It utilises two standards, 
an HIV-1 integrase DNA standard to quantify cell associated DNA and a CCR5 standard which is 
used to quantify the total amount of cells assayed in each sample as each diploid human cell 
(including peripheral blood mononuclear cells) contains two copies of this gene.  
Prior to starting the assay the DNA concentration of each extracted sample was measured using a 
Nanodrop 1000 spectrophotometer. Sample concentrations above 120 ng/µL were diluted down to 
a final concentration of 120 ng/µL. This was to prevent over saturation of the assay with human 
genomic DNA which could lead to inhibition. Following this the appropriate amount of master mix 
was prepared according to the optimised reagent concentrations depending on the amount of 
samples to be assayed (Table 2.5).  
Table 2.5 Master Mix calculations for real time PCR assay 
HIV-1 and CCR5 Master mix (Sample DNA and Standard)* 
Reagent Stock 
Concentration 
Final 
Concentration 
Volume per 
reaction (µL) 
Molecular grade water -- -- 1.97 
2X LCM 2X 1X 12.5 
P1 100 µM 0.9 µM 0.23 
P2 100 µM 0.9 µM 0,.23 
Probe 100 µM 0.3 µM 0.075 
Total cocktail -- -- 15 
Sample -- -- 10 
Total Volume 25 
*Primers used can be found in Addendum A5
A 96 well plate was placed on a cooling block and 15 µL of the master mix distributed into the wells 
of the plate according to the layout in Figure 2.6. The plate was sealed with aluminium foil to 
prevent probe exposure to light. Invitrogen TaqMan Control genomic DNA was used as the CCR5 
standard and serially diluted from a stock concentration of 16667 cells/µL down to 1042 cells/µL 
using a 1:1 dilution by combining 25 µL of stock DNA with 25 µL of 5 mM Tris solution and 
repeating until the desired concentration was reached. Before adding sample DNA to the wells 
containing CCR5 master mix the DNA extracted from participant samples were diluted to prevent 
inhibition of the real-time assay because CCR5 is abundant in genomic DNA. A 1:30 dilution of 
each sample was prepared by first preparing a 1:10 dilution by combining 10 µL of sample with 90 
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µL 5 mM Tris and then 10µL of the 1:10 dilution is combined with 20µL of 5 mM Tris to reach a 
dilution of 1:30 of each sample. Once all samples have been diluted the total HIV-1 DNA standard 
was prepared by serially diluting HIV-1 DNA  from a stock concentration of 1  x105 copies/µL down 
to 3 copies per well. This was done by combining 18.75 µL of the standard HIV-1 DNA with 40.5 µL 
of 5 mM Tris and repeating this step until 3 copies per well was reached. After preparing all the 
necessary dilutions the samples and standards were aliquoted into the respective wells according 
Figure 2.6. The plate was covered with a clear film and the edges firmly secured to prevent 
evaporation during the PCR run. The plate was transferred on the cooling block to the CFX 
Connect (Bio-Rad Laboratories, USA) and the samples were run using the following cycle 
specifications: Step 1: 95⁰C for five minutes, Step 2: 95⁰C for 15 seconds, Step 3: 60⁰C for one 
minute and then step 2-3 was repeated for 50 cycles and then a final hold step at 37⁰C was set. 
After completion of the run the results were analysed using Bio-Rad CFX Manager version 3.0 
software.   
 
Figure 2.6 Plate layout for iCAD assay. 
2.8 Statistical analyses 
All statistical analyses were performed using R software version 3.3.1 (with earlier datasets) or 
3.4.3 (with later datasets). Figure 2.7 provides a summary of the statistical workflow used. 
Spearman rank order correlations were used to assess what clinical variable could predict study 
end point HIV-1 DNA. Mixed effect regression models were used to determine what variables 
would be independent predictors of total HIV-1 DNA decay: including baseline HIV-1 DNA, pre-
treatment HIV-1 viral load, absolute CD4 count, age-initiated, time interrupted and study arm as 
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fixed effects and the participant as the random effect. Decay slopes were described using mixed 
effect models (participant as random effect and time-treated as fixed effect), separately for very 
early treated children and interrupted or non-interrupted CHER patients. These mixed effect 
models enabled us to combine data from all individuals, with an overall good fit, as the random-
effects adjust for individual differences in intercepts and slopes, while enabling one to assess the 
association of fixed effects with the outcome (HIV-1 DNA concentration) across all individuals. 
While time on treatment is the strongest predictor of HIV-1 DNA concentration in a decay model, 
other fixed effects were assessed in terms of their influence on the rate of decay. Total HIV-1 DNA 
decay rates were presented as half-life (t ½) for intuitive comparison between groups and with 
other published studies.  
 
Figure 2.7 Statistical Analysis Workflow 
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Chapter 3: Results 
The results are presented in five main sections. The first section highlights the results from the 
experiment designed to determine the amount of lymphocytes present in a dried blood spot and 
the second section focuses on the results from the HIV-1 integrase standard limiting dilution assay. 
The third section highlights the results from the very early infant diagnosis (VEID) cohort; which 
included infants who initiated treatment within eight days following birth which corresponds to aim 
one, objective one of this research project. The fourth section contains the results from the CHER 
and Post-CHER cohort; which included children who initiated treatment at varying time points 
according to study specific criteria. The results from this cohort correspond to aim one, objective 
two; and aim 2 objective 3 of the study. Lastly, in the fifth section the VEID and CHER/Post-CHER 
HIV-1 DNA decay kinetics results are compared for further discussion in chapter four. 
3.1 Total amount of peripheral blood mononuclear cells (PBMCs) in a DBS sample 
To determine the amount of peripheral blood mononuclear cells there are in a dried blood spot 
sample two negative samples were recruited, labelled Neg 1 and Neg 2 with a blood volume of 250 
µL and 300 µL, respectively.  For each sample a 50µL dried blood spot was made and PBMCs 
were isolated from the remaining blood volume. DNA was extracted from both DBS and EDTA 
whole blood PBMC samples and a real-time PCR assay using primers to amplify CCR5 were used 
to quantify the amount of cells assayed in each sample. The total amount of cells assayed was 
normalized by sample volume to determine total cells assayed per microliter in DBS and PBMC. 
These values were used to determine the relative yield of cells assayed in a DBS (PBMC and 
polymorphs) compared to the number of PBMC recovered from the same volume of whole blood. 
The relative yields are summarized in Table 3.1. In Neg 2, relatively fewer cells were recovered 
from DBS when normalized to the same volume of whole blood PBMC. A higher relative cell 
recovery was expected because a DBS sample also contains polymorphic cells and the observed 
lower than expected yield could be due to PCR inhibition or poor DNA extraction yield from the 
DBS sample. In contrast in Neg 1, relatively more cells were recovered in the DBS, likely due the 
fact that polymorphs are also present in the DBS sample. Apart from variable ratios of PBMC to 
polymorphs, variable extraction efficiency and PCR inhibition of DBS samples; random variation 
due to small sample volume could have contributed to the lack of reproducible yield. This high 
variability observed in these two control samples suggested that we would not be able to use DBS 
for accurate quantification of pre-treatment HIV-1 DNA load, but we could nevertheless use these 
samples to qualitatively determine if a particular individual had amplifiable HIV-1 DNA with the 
iCAD assay primers and probe. This was important especially in cases where HIV-1 DNA loads 
may decrease rapidly on combination antiretroviral therapy and become undetectable at the first 
follow-up visit due to low concentration of nucleic acids.  
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Table 3.1 Percentage PBMCs in a dried blood spot.  
Sample name Sample Type  
Neg1 DBS PBMC % PBMC assayed in 
DBS 
Total cells assayed 28153 87733  
Sample volume (µL) 50 200  
Total cells per µL 563,06 438,665 77,91% 
Neg2    
Total cells assayed 27551 274712  
Sample volume (µL) 50 250  
Total cells per µL 551,02 1098,848 199,42% 
 
3.2 Limiting dilution results of the HIV-1 DNA integrase standard for the iCAD assay 
A limiting dilution experiment was conducted to verify optimal assay performance and to verify that 
the HIV-1 DNA integrase standard for the iCAD real time PCR assay was prepared correctly and 
stored at the correct concentration of 1 x105 copies per microliter. In this experiment the standard 
was serially diluted down from the stock concentration above down to one copy per well and 
loaded onto a real-time PCR (qPCR) run in replicates of 10. As expected all the replicates of the 
standards at higher concentrations (Std-3 to Std-8) were detected and at the lower concentrations 
(Std-1 and Std-2) only 5 replicates were detected at the concentration of one copy per well; and 
nine replicates were detected at the concentration of three copies per well. At the lower 
concentrations we expect to detect less replicates across the wells due to distribution statistics. 
The mean cycle threshold decreases at the higher standard concentrations because samples are 
detected earlier during the real-time PCR run because there is a greater abundance of the target 
and it is more easily detected as opposed to the lower concentrations which require more 
amplification cycles to enable detection. Figure 3.1 shows the early detection of higher 
concentrations (indicated in black and navy blue) versus detection at later cycles at the lower 
concentrations (indicated in light blue and pink). From the standard curve (Figure 3.2) an efficiency 
(E-value) of 97.0% was calculated and this correlates to a slope value of -3.396 and the correlation 
of coefficient value (R2) was calculated as 0.98.  
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Table 3.2 Summary of the qPCR limiting dilution assay 
Limiting Dilution Assay qPCR results 
Sample Dilution (HIV-1 
integrase copies per 
10µl) 
Number of replicates 
detected (out of 10) 
Mean Cycle 
threshold (Ct) 
Std-1 1  5 41,97 
Std-2 3 9 40,01 
Std-3 10 10 38,08 
Std-4 30 10 36,89 
Std-5 100 10 34,81 
Std-6 300 10 33,23 
Std-7 1000 10 31,37 
Std-8 3000 10 30,05 
 
 
 
Figure 3.1 Limiting dilution assay amplification plot results 
Legend 
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 Figure 3.2 Limiting dilution assay standard curve. The open circles represent the different 
standards from 3000 copies per well to 1 copy per well and multiple circles represent the amount of 
replicates.  
3.3 Very Early Infant Diagnosis (VEID) cohort 
3.3.1 iCAD assay characteristics  
The iCAD assay was performed on 15 patients, but only 11 were selected for further analysis of 
which we tested a median of four samples (or time points) per patient for a study period of one 
year.  Table 3.3 provides a summary of the median iCAD value (total HIV-1 DNA copies per million 
cells) and the mean number of cell equivalents assayed at each time point for all 11 patients. From 
the summary we observed a decrease in the iCAD value from the baseline time point down to the 
last visit. The median iCAD value decreased from 714.4 copies per million cells to 48.9 copies per 
million cells, from baseline to the first study visit, thereafter the median iCAD value decreased by 
smaller increments until the last study visit. We also observed a large difference between the mean 
number of cells equivalents assayed at baseline versus the other time points (visit 1 – visit 4) and 
this is most likely due to the difference in the sample type because all baseline samples were DBS 
samples and the study visits were PBMC samples.  
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Table 3.3 Summary of iCAD assay characteristics for the VEID cohort 
* Includes only the 11 participants selected for further HIV-1 DNA and HIV-1 RNA kinetics analysis. Sample also refers to
the number of time points tested.
3.3.2 Participant characteristics 
A total of 15 participants were selected for the study because they had a baseline sample available 
and two on-treatment samples. However, four participants were excluded from HIV-1 DNA and 
HIV-1 RNA decay analysis. Two infants had no detectable plasma HIV-1 RNA and total HIV-1 
DNA, and another two only had detectable HIV-1 RNA. Table 3.4 is a summary of the remaining 11 
infants who initiated ART between 0-8 days (median 4 days) and with an average baseline HIV-1 
RNA of 3.9 log copies/mL. Seven infants were classified as suppressed (plasma HIV-1 RNA load 
<100 copies/mL after 6 months on ART) and four were classified viremic. All participants were part 
of a child PMTCT program consisting mainly of a dual regimen (NVP. AZT), but two were initiated 
on immediate combination antiretroviral therapy.  
iCAD assay participants 
Number of patients tested 15 
Number of samples tested per 
patient* (Median ([QR]) 
4 [4-5] 
iCAD assay summary 
Visit number 
Median iCAD value (total HIV-1 
DNA copies per million cells)  
[IQR] 
Mean number of cells 
equivalents assayed 
Baseline 717.4 [516.5-1722.5] 131619 
Visit 1 48.9 [0.0-509.3] 579557 
Visit 2 11.4 [0.0-107.0] 556598 
Visit 3 18.0 [0.0-35.05] 703159 
Visit 4 0.3 [0.0-6.6] 627513 
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Table 3.4 Participant characteristics for the VEID cohort 
Participant characteristic  Total number of participants (n=11) 
Child PMTCT drugs NVP,AZT (n=7) 
NVP (n=1) 
Immediate cART (n=2) 
AZT,3TC (n=1) 
Initial ART regimen* AZT,3TC, NVP (n=11) 
Age at ART initiation (days); median(IQR) 4.0 (3.0– 7.0) 
Average  Baseline HIV-1 RNA (log copies/mL) 3.9 (2.6-4.7) 
Virologic status (6 months after ART) Suppressed (n=7); Viremic (n=4) 
Study period (months); median(IQR) 6.9 (3.5-11.6) 
*NVP replaced by LPV/r at corrected age of 42 weeks; AZT replaced by ABC at approximately 3 months of age 
3.3.3 HIV-1 DNA and HIV-1 RNA kinetics  
Of the seven suppressed infants, HIV-1 RNA was undetectable (<100 copies/mL for 200 microliter 
input) in three infants within 3.4 months and in one participant HIV-1 RNA reached a 120 
copies/mL at 3.5 months. In the remaining three the first undetectable plasma HIV-1 RNA loads 
were recorded between six and seven months. Total HIV-1 DNA decay kinetics were characterised 
in seven suppressed participants. Pre-treatment DBS samples were used to determine if there was 
a detectable baseline HIV-1 DNA load, but we could not characterize the decay from baseline to 
first on-ART time point. Total HIV-1 DNA decay was measured from the first time point to last time 
point for the study period (Figure 3.3).HIV-1 DNA decay slopes showed a good log-linear 
correlation with a mean half-life of 64.8 days and a conditional R2 (95% CI) of 0.77 (0.53-0.91). At 
the end of the study period, six out of seven participants’ total HIV-1 DNA loads decreased to less 
than ten copies per million PBMCs. One participant of the six had an undetectable HIV-1 DNA load 
at the second study visit, 3.5 months on ART (participant S9) and another participant (participant 
S3) had a detectable HIV-1 DNA load at 11.6 months, but it was unquantifiable by our assay. 
Furthermore, one of the seven participants (participant S6) who had delayed viraemia suppression 
had a total HIV-1 DNA load remaining above 10 copies per million PBMCs, only dropping down to 
47.8 copies per million PBMCs at the end of the observation period for this participant. Of the 
participants classified as viraemic, two participants (V3 and V5) had early undetectable HIV-1 DNA 
at their first study visits with subsequent viraemia. Participant V5 had continued viraemia along 
with an increase in HIV-1 DNA whereas participant V3 had a single episode viraemia with HIV-1 
DNA remaining undetectable. Participant V1 had an undetectable plasma HIV-1 RNA load at a 
second study visit, but HIV-1 DNA remained detectable at that time point and continued to increase 
thereafter. Participant V4 had a decrease in HIV-1 DNA load despite on-going detectable viraemia.  
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Figure 3.3 HIV-1 DNA and RNA kinetics in the VEID cohort. “S” indicates suppressed infants 
and “V”, viremic infants. HIV-1 DNA loads are denoted by black circles and plasma HIV-1 RNA 
loads are denoted by grey triangles. Open icons indicate HIV-1 DNA or HIV-1 RNA below the limit 
of detection: plasma HIV-1 RNA load was censored at <100 copies per mL and HIV-1 DNA loads 
at <3 copies per million PBMCs. HIV-1 DNA and RNA decay slopes were determined in the seven 
suppressed infant s. 
In summary, we observed a rapid viral suppression after treatment started very early after 
infection. Six out of seven participants’ total HIV-1 DNA load decreased to less than 10 copies per 
million PBMCs, with one participant having delayed viraemia suppression. Overall there was a fast 
decay rate (mean t ½ of 64.8 days).  
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3.4 Children with HIV early antiretroviral therapy (CHER) cohort and Post-CHER 
cohort 
3.4.1 iCAD assay characteristics 
The iCAD assay was performed on 40 patients from the CHER and Post-CHER cohort. We tested 
a median of five samples (or time points) per patient for a study period of up to 10 years.  Table 3.5 
provides a summary of the median iCAD value (total HIV-1 DNA copies per million cells) and the 
mean number of cell equivalents assayed at each time point for all 40 participants. The mean 
number of cell equivalents assayed across all time points was relatively the same. The median 
iCAD value decreased over time from baseline to the last study visit. We observed a similar trend 
as in the VEID cohort, where there was a large decrease in the median iCAD value from the 
baseline time point (1601.5) to the first sample six months (90.4) after baseline. The baseline 
sample taken prior to re-initiation of therapy only applies to participants who were therapy 
interrupted. After six months the median iCAD value decreased more gradually until the last study 
visit time point. 
Table 3.5 Summary of iCAD assay characteristics for the CHER/Post-CHER cohort 
iCAD assay participants  
Number of patients tested 40 
Number of samples tested per patient 
(Median [IQR]) 
5 [5-7] 
iCAD assay characteristics per visit   
Visit ID 
Median iCAD value (total 
HIV-1 DNA copies per 
million cells)  [IQR] 
Mean number of cells 
equivalents assayed 
Baseline 1601.5 [739.75-3271.20] 527462 
Baseline prior to re-initiation of therapy* 831.9 [313.45-1372.90] 591327 
6 months 90.4 [43.20-424.80] 522851 
12 months 93.0 [61.125-343.60] 503074 
18 months 91.0 [18.0-232.20] 484458 
7/8 years (Post-CHER Visit 1) 21.2 [6.75-39.95] 461445 
9/10 years (Post-CHER Visit 4) 22.5 [0.75-46.0] 505591 
*Only applies to patients who were therapy interrupted 
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3.4.2 Participant characteristics 
A total of 40 participants were tested, but only 31 were selected for further analyses. These 
individuals were viraemia-suppressed (viral load less than or equal to 200 copies per millilitre 
across two or more time points) and met the criteria (stated in section 2.3.3) which made them 
suitable candidates to study HIV-1 DNA decay and potential  predictors associated with decay. 
Table 3.6 provides an overview of the participant characteristics for this cohort. Fifteen of the 
participants came from Part A, Arm 2 of the CHER study; eight came from Part A, Arm 3; six came 
from Part A, Arm 1 and two from Part B, Arm 2 of the study. Furthermore, eight of the 31 were 
never interrupted and had continuous antiretroviral therapy. Two participants who were never 
interrupted were initially recruited into a study arm with a scheduled interruption period, but due to 
clinical reasons they were continued on therapy. All participants were initiated on a triple regimen 
of zidovudine (AZT), lamivudine (3TC) and lopinavir-ritonavir (LPV/r), except one who started with 
stavudine (D4T) instead of zidovudine as part of their treatment regimen. The median age of ART 
initiation was 58 days and for the subset that was never interrupted the median ART initiation age 
was 156.5 days. The median CD4 percentage was 17.9% and the absolute CD4 count 691 cells 
per microliter at baseline or prior to continuous therapy. At the end of this study period the median 
age of the participants at the last sample time point was 9.8 years, the median CD4 percentage 
was 37% and the absolute CD4 count 948 cells per microliter. 
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Table 3.6 Participant characteristics for the CHER and Post-CHER cohort. CHER study arms. 
A1: Part A, Arm 1; A2: Part A, Arm 2; A3: Part A, Arm 3; B1: Part B, Arm 2.  
Participant 
characteristic 
All(n=40) Subset: 
Viraemia-
suppressed 
(n=31) 
Subset: Viraemia-
suppressed and 
never 
interrupted(n=8) 
Treatment regimen  AZT, 3TC, LPV/r 
(n=36); 
AZT, 3TC, LPV/r then 
ABC, 3TC, LPV/r
 (n=1); 
D4T, 3TC, LPV/r 
(n=1); 
ABC, AZT, 3TC then 
ABC, 3TC, LPV/r(n=1); 
ABC, DDI, NVP then 
AZT,3TC,EFV then 
ABC, 3TC, LPV/r (n=1) 
D4T, 3TC, LPV/r 
(n=1); 
AZT, 3TC, LPV/r 
(n=30) 
 
AZT, 3TC, LPV/r  
Study arms  A1(n=8) 
A2(n=18) 
A3(n=10) 
B2(n=4) 
A1(n=6) 
A2(n=15) 
A3(n=8) 
B2(n=2) 
A1(n=6) 
A3(n=2) 
Interruption status  Interrupted (n=27) 
Never interrupted 
(n=13) 
Interrupted (n=23) 
Never interrupted 
(n=8) 
- 
Never 
interrupted(n=8) 
Age ART initiated 
(days); median(IQR) 
64(52-82.5) 
 
58 (51.5-77) 156.5 (110.3-256.8) 
 
CD4% nadir *; median 
(IQR) 
17.6% (14.5-23.6%) 17.9 (15.15-24.15) 16.9 (14.0-19.1) 
Absolute CD4 count 
nadir cells/microliter *; 
median (IQR) 
676.5(478.5- 996.5) 691 (505-1038.5) 505(440.5-759.5) 
 
Time interrupted 
(days); median (IQR) 
98(0-254) 133 (0-247) 
 
_ 
 
 
Age at last sample 
(years); median (IQR) 
10(8.7-10.6) 9.8(8.8-10.6) 9.5 (9.3-10.2) 
CD4% at last sample 37% (34-42%) 
 
37 (34-43) 40 (32.75-43.5) 
Absolute CD4 (cells/ 
microliter) at last 
sample  
943(801-1089) 948 (841-1134.5) 
 
981 (955.25-1133.75) 
 
ART: antiretroviral therapy; IQR: interquartile range; CHER:  
*(before continuous treatment); Duration of interruption was  
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3.4.3 Fitting decay HIV-1 DNA decay curves  
Most individuals did not have a fixed log linear decay across time and HIV-1 DNA decay rate 
seemed to decrease over time. In Figure 3.4 the time treated (x-axis) was transformed to square 
root of days treated and provided the best fit for the data with a conditional R2 of 82% (compared to 
a conditional R2 of 73% without square root transformation of time treated).  
 
Figure 3.4 HIV-1 DNA decay: cubic model of 31 viraemia-suppressed participants. 
 
3.4.4 Impact of therapy interruption 
Wilcoxon rank sum tests were used to assess pre-interruption, post-interruption and endpoint HIV-
1 DNA levels. This is a non-parametric statistical measure was used as the data is not normally 
distributed and accounts for the variability seen among participants. Figure 3.5 shows that there 
was no significant difference between pre-interruption log HIV-1 DNA versus post-interruption log 
HIV-1 DNA (W = 353, P= 0.18). In contrast, there was a significant difference in post-interruption 
HIV-1 DNA levels versus endpoint log HIV-1 DNA (W= 558, p<0.001). The impact of therapy 
interruption on the CD4 percentage and absolute CD4 count at the end of the study was 
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determined using a Spearman rank correlation test by plotting days interrupted against CD4 
percentage and absolute CD4 count at the end of the study. This test is used to assess the 
relationship between two variables and can indicate the strength of the relationship and whether it 
is a negative or positive association. In figure 3.6 we see no significant correlation between both 
parameters and period of therapy interruption.  Furthermore, there was no significant correlation 
between the period of interruption and study endpoint HIV-1 DNA (Spearman rho = 0.35; p 
=0.055). However, there is a trend toward higher HIV-1 DNA levels and longer periods of 
interruption (Figure 3.7a). Additionally, two arbitrary categories of interruption were compared, 
interruption for less than 58 days (lower tertile) versus interruption for at least 58 days. The lower 
tertile (<58  days) had a significant Wilcoxon Rank Sum test p-value of 0.18 and may  suggest that 
shorter periods of interruption may not have an effect on total HIV-1 DNA level at end of the study 
(Figure 3.7 b).  
 
 
Figure 3.5 Pre- and post-interruption HIV-1 DNA and endpoint HIV-1 DNA (n=27). 
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Figure 3.6 Impact of therapy interruption on CD4% and absolute CD4 count at the end of the 
study. a) The Spearman rank correlation (rho) shows no significant correlation between period of 
interruption in days versus the CD4% at the end of the study (rho = 083; p = 0.7).  b) Spearman 
rho = -0.057; p = 0.76, therefore there is no significant correlation between period of interruption 
and absolute CD4 count.  
 
a) 
b) 
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Figure 3.7 Impact of therapy interruption on study endpoint HIV-1 DNA. a) There is no 
significant correlation between the period of interruption and study endpoint HIV-1 DNA (Spearman 
rho = 0.35; p =0.055). b) The lower tertile (<58 days) had a significant Wilcoxon Rank sum test p-
value of 0.18. 
3.4.5 Predictors of total HIV-1 DNA decay 
HIV-1 DNA level before treatment (p<0.0001), increased HIV-1 DNA concentration over a period of 
interruption (p<0.01) and a higher absolute CD4 count pre-therapy (p = 0.01) predicted a slower 
decay (Table 3.7). A faster decay rate was observed in participants from the Arm 3 group of the 
a) 
b)
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study who had a longer initial period of therapy (96 weeks) before the start of an interruption 
period, but two of these children were not interrupted. However, the association remained 
significant after controlling for interruption (p = 0.02). Other variables such as CD4% nadir before 
treatment (p=0.38), pre-treatment HIV-1 RNA (p=0.051), age-starting ART (p=0.73), time-
interrupted (p=0.76) and viraemia copy years during interruption (p=0.98) were not found to be 
independent significant predictors of HIV-1 DNA decay. 
 
Table 3.7 Mixed effect model of log HIV-1 DNA decay against the square root of time on 
continued treatment 
Fixed effects  Estimate Std.Error 
  
degrees of 
freedom 
t-value p-value  
(Intercept) 1.2487 0.5750 18.4046 2.1710 0.043 
Square root of days treated  -0.0274 0.0019 102.5555 -14.5950 <0.0001 
CD4% nadir before treatment  -0.0131 0.0146 17.2068 -0.8950 0.38 
Absolute CD4  nadir before 
treatment  
0.0006 0.0002 17.4915 2.7870 0.01 
Pre-treatment HIV-1 DNA level  0.8016 0.1109 16.1337 7.2260 <0.0001 
Change in HIV-1 DNA levels 
over interruption 
0.8508 0.2521 21.6229 3.3750 <0.01 
pre-treatment HIV-1 RNA level  -0.1719 0.0817 16.4751 -2.1030 0.051 
Viraemia copy years during 
interruption  
-0.0021 0.0760 18.9584 -0.0280 0.98 
Age ART started  0.0003 0.0009 50.4246 0.3500 0.73 
Time interrupted 0.0003 0.0009 19.3851 0.3050 0.76 
Continuous vs. interrupted 
therapy  
0.0525 0.2935 15.8483 0.1790 0.86 
Study arm A2 (vs. A1) -0.4774 0.3919 19.1950 -1.2180 0.24 
Study arm A3 (vs. A1) -0.8794 0.3554 20.3218 -2.4740 0.022 
Study arm B2 (vs. A1) -0.0192 0.4420 20.5826 -0.0440 0.97 
 
3.5 Comparison of total HIV-1 DNA decay in the VEID and CHER cohorts 
The first derivative (slope) of log10 HIV-1 DNA against the square root of time was used to calculate 
point estimates of total HIV-1 DNA half-life (t ½) in eight viraemia-suppressed participants who 
were never therapy interrupted and 23 viraemia-suppressed participants who were previously 
interrupted before starting continuous therapy at a median of 20 months post-interruption. The 
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square root of time was treated as a fixed effect and participant ID was treated as a random effect 
in a cubic mixed effect model. The conditional R2 (95% CI) values for the HIV DNA decay curve 
was 0.82 (0.65-0.93) for the VEID infants (early ART start, n=7), 0.85 (0.67-0.94) for the CHER 
children (late ART start, n=8) and 0.79 (0.68-0.86) for the CHER children with previous interrupted 
ART (n=23). At 6 months of treatment, in the eight never-interrupted viraemia-suppressed 
individuals, who started treatment around five months of life the t ½ of HIV-1 DNA was 9.2 (95% 
CI: 7.4-12.1) months, significantly slower than the 2.7 months (95%CI: 2.1-3.8) t ½  seen in seven  
viraemia-suppressed infants who started ART around four days after birth (p<0.01) (Figure 3.8  a-
b). The observed decay rate in previously interrupted CHER children (n=23) was 9.6  months 
(95%CI: 7.6-12.6) t ½ (Figure 3.8  c); which was similar to the half-life observed in 8 CHER 
children who were never interrupted, but started later on ART (p=0.81; Wilcoxon Rank Sum Test) 
 
 
 
Figure 3.8 Comparison of total HIV-1 DNA decay rates in participants who were initiated 
early on ART versus later ART initiation and previously interrupted participants.   
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Chapter 4: Discussion 
4.1 Assay validation  
4.1.1 Variable cell yield from dried blood spots 
Cellular DNA recovery from DBS samples were variable, when quantified using a real-time PCR 
assay targeting the human CCR5 gene. From the two samples we could retrieve that had sufficient 
volumes, one sample (Neg 2) had relatively fewer cells recovered from DBS when normalized to 
the same volume of whole blood PBMC. A relative higher cell recovery was expected because a 
DBS sample also contains polymorphonuclear leucocytes (predominantly neutrophils), and this 
lower than expected yield could be due to PCR inhibition or poor DNA extraction yield from the 
DBS sample. In contrast in the Neg 1 sample, relatively more cells were recovered from the DBS 
sample and this is likely due the fact that polymorphs are also present in the DBS sample. Apart 
from the variable ratios of PBMC to polymorphs, variable extraction efficiency and PCR inhibition of 
DBS samples; random variation which is expected to be higher when extracting few cells (due to 
small sample volume) could have contributed to the lack of reproducible yield. This high variability 
observed in these two control samples suggested that we would not be able to use DBS samples 
to accurately quantify baseline HIV-1 DNA load, but could nevertheless use DBS samples to 
qualitatively determine if HIV-1 DNA from a particular individual was detectable with the iCAD 
assay primers and probe. This was important to show as HIV-1 DNA loads may decrease rapidly in 
infants receiving combination antiretroviral therapy and could have become undetectable at their 
first study visit when EDTA blood was collected.  
4.1.2 Accurate quantification of integrase HIV-1 DNA standard for iCAD assay 
At HIV-1 standard dilutions of three copies per well and one copy per well, respectively 9 out of 10 
and 5 out of 10 replicates were detectable. This agreed with the expected proportion of positives 
(or expected hit rate) according to the Poisson distribution, which provides support that the HIV-1 
integrase standard used for the iCAD assay was prepared and stored at the correct concentration 
of 1  x105 copies per microliter. A valid real-time PCR run should have an efficiency value (E-value) 
between 90%-110% which corresponds to a slope of between -3.58 and -3.10. The correlation of 
coefficient (R2) should be as close to 1 as possible, for this study a R2 above 0.95 was considered 
acceptable. These criteria were used for all real-time PCR assays in this thesis. The limiting 
dilution experiment standard curve (Figure 3.2) shows a slope value of -3.396 which corresponds 
to an efficiency (E-value) of 97.0% and the correlation was (R2) was 0.98. This verifies that the 
qPCR run was acceptable according to the above criteria and results from the limiting dilution 
assay were valid.   
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4.2 Infants diagnosed and treated very early after birth (VEID cohort).  
4.2.1 Rapid HIV-1 DNA and RNA decay after very early ART initiation 
In infants with rapid plasma HIV-1 RNA suppression, who reached less than 100 copies/mL within 
3.4 months on ART, total HIV-1 DNA became undetectable in three out of eleven infants at 6 days, 
3.5 months and 4 months, respectively. The initial phase of decay between ART initiation and first 
study visit could not be assessed because HIV-1 DNA could not be accurately quantified on DBS 
samples from pre-treatment. The decay rate of total HIV-1 DNA in PBMC samples (taken from the 
first study visit onwards) was 65 days (t ½). In a study where adults were treated in the acute 
phase of HIV infection (Fiebig stage I and II) a rapid decay was observed with a half-life of 21 days 
in the first two weeks thereafter a much slower decay was observed at a half-life of 198 days 
(Ananworanich et al., 2016). In children initiated on therapy within two months of birth total HIV-1 
DNA decay at 24 weeks of life was 53 days (t ½ ) and a decay rate of 124 days (t ½ ) was seen 
between 24 and 48 weeks of life (Uprety et al., 2015).  Another study in children who initiated 
therapy within three months after birth reported a half-life of 107 days in the first year of life 
(McManus et al., 2016). Therefore, HIV-1 DNA decay observed in our study was faster than what 
was seen in other similar studies.  
The possible reasons for rapid HIV-1 DNA decay within the blood of infants treated shortly after 
birth could be due to a lower starting quantity of infected cells (pre-treatment) as a result of 
maternal ART and infant prophylaxis. Another reason could be the rapid loss of cells with 
unintegrated virus (Ananworanich et al., 2016) and a high CD4 turnover with a large proportion of 
short-living infected CD4 cells that decay rapidly (Schönland et al., 2003). Furthermore, a large 
proportion of infected cells could contain integrated HIV-1 DNA that may be defective and contain 
deletions and this non-intact virus could result in a negative (undetectable) result on our iCAD 
assay (Bruner et al., 2016).  
4.2.2 Implications of rapid decay for infant HIV-1 diagnosis 
Rapid early phase HIV-1 RNA and DNA decay poses a diagnostic challenge in infants receiving 
extensive neonatal prophylaxis. Additionally, starting concentrations of HIV-1 DNA or RNA, in 
treated infants may be very low due to maternal ART (effectively intra-uterine treatment of infected 
babies), and possibly some ARV absorption through breastfeeding (Waitt et al., 2015) that may 
together contribute to suppression of viral replication after infection. HIV-1 DNA and RNA could be 
so low that it could result in false negative diagnostic tests. It is therefore crucial that a definitive 
diagnosis is established as soon as possible after birth before HIV-1 DNA or plasma HIV-1 RNA 
become undetectable. 
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4.3 Children with HIV early antiretroviral therapy (CHER) and Post-CHER cohort 
4.3.1 Relatively slower Total HIV-1 DNA decay with later ART initiation  
In the eight viraemia-suppressed children who were never therapy interrupted and who started 
ART around 5 months of life; the decay of HIV-1 DNA was much slower than in children who 
started around a median of 4 days of life, 9.2 months (t ½) versus 2.7 months (t ½), respectively. 
Other studies found lower HIV-1 DNA levels in children who started ART before 3 months (Kuhn et 
al., 2018; Luzuriaga et al., 2014; Martínez-Bonet et al., 2015; McManus et al., 2016; Van Zyl et al., 
2015), before 6 months (Ananworanich et al., 2014) and before one year of age (Foster et al., 
2017) versus later ART initiation. A recent article from a European cohort also showed that earlier 
ART start and better virologic suppression in infants was associated with lower total HIV-1 DNA at 
age 4-11 years (Tagarro et al., 2018). An earlier study also reported a faster decrease in HIV-1 
DNA levels within in a group of infants who achieved virologic suppression  within first year of life 
versus infants who achieved virologic control between 1-5 years of age (Uprety et al., 2017). 
However, when assessing HIV-1 DNA decay a study investigating longitudinal samples found no 
difference in the rate of decay (McManus et al., 2016) in children starting ART earlier than three 
months or later. This suggests that there may be a very early window when the pool of HIV-1 
infected cells is more labile.  
There was no significant difference in HIV-1 DNA decay rates between the group of CHER children 
who started treatment around 5 months( t ½ of HIV-1 DNA 9.2 (95% CI: 7.4-12.1) months) 
(p<0.01) and in the 23 who started around a median of 1.8 months, who interrupted for a median of 
7 months, and reinitiated at a median of 20 months (HIV-DNA t ½ 9.6(95%CI: 7.6-12.6) months 
post-interruption (p=0.81). This is in contrast to another study that investigated the impact of short 
term interruption on HIV-1 DNA decay in infants who initially started continued ART at a median of 
4.8 months with a subsequent short interruption period for a median of 106 days. Following the 
resumption of ART at around 15 months post-interruption and following plasma HIV-1 RNA re-
suppression, they found a slower HIV-1 DNA decay rate after interruption versus the initial decay 
rate observed after initiating continued ART (Pankau et al., 2018). However, in the CHER trial 
children who electively started early were randomized to interruption, whereas those who started 
based on clinical and immunological criteria generally started later and were not interrupted. It was 
therefore not possible to isolate the effects of interruption and early start on HIV-1 DNA decay 
amongst the CHER patients.  
4.3.2 Predictors associated with decay  
In this study the strongest predictors of a slower decay rate were pre-treatment HIV-1 DNA levels 
and the change in HIV-1 DNA before versus after interruption. Higher pre-treatment HIV-1 DNA 
levels and an increase in HIV-1 DNA over the period of interruption resulted in a slower decay 
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following the restart of continuous therapy. Patients were reinitiated on treatment based on CD4 
measures and other clinical criteria, patients with more rapid progression during interruption were 
initiated faster. This could have counteracted any increased replenishment with longer periods of 
interruption. Participants with an initial treatment period of 96 weeks (prior to interruption) had a 
faster decay rate and this suggests an early period of prolonged therapy may be valuable in 
limiting HIV-1 persistence.  
4.3.3 No significant changes in total HIV-1 DNA levels pre- and post-interruption 
Overall, there was no significant difference in HIV-1 DNA levels pre-interruption versus post-
interruption. Only when the lower tertile of period of interruption (<58 days) was compared to the 
rest of population, was there a significant lower total HIV-1 DNA level at the end of the study 
period. In a cohort of chronically HIV-1 infected adults undergoing at least one short analytical 
treatment interruption (ATI), for a period of six weeks or less, there was no difference found in HIV-
1 DNA levels pre-ATI and post-ATI following resumption of ART and plasma HIV-1 RNA re-
suppression (Papasavvas et al., 2018). Another study conducted in adults with a median ATI 
phase of 57 days also found no lasting effect of interruption (Clarridge et al., 2018). During ATI 
plasma HIV-1 RNA and HIV-1 DNA levels increased, but following re-initiation of ART and after a 
median of 363 days, HIV-1 DNA levels declined to pre-ATI levels.  
Our study also found no significant correlation between CD4 percentage and absolute CD4 count 
at the end of study with duration of therapy interruption phase. This is not surprising as the CHER 
study reinitiated children based on CD4 count or other clinical criteria, which could have 
counteracted any effect of prolonged interruption on CD4 count. Similarly, another study found no 
significant lasting differences in pre-ATI and post-ATI CD4 count or CD4 percentage. Despite a 
transient decrease in CD4+ T cells during interruption upon re-initiation of treatment the levels of 
CD4+ T cells returned to pre-ATI levels (Clarridge et al., 2018).  
4.4 Summary of the scope of the study 
4.4.1 Strengths and limitations of the study 
When considering infants who were diagnosed and treated, shortly after birth (VEID cohort), 
infants were diagnosed in a public health setting and recruited only later in the study upon 
confirmation of positive HIV diagnosis. PBMC samples were not available for baseline HIV-1 DNA 
load testing and DBS samples were utilised. We attempted to normalize DBS samples by the 
amount of amplifiable cell equivalents, but due to variable cell recovery and DBS including 
polymorphonuclear cells we were not able to accurately quantify the amount of HIV-1 DNA in DBS. 
In addition, the lack of frequent sampling soon after therapy initiation prevented us from definitively 
determining whether the initial decay HIV-1 DNA decay was log-linear or biphasic. The iCAD assay 
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detects total HIV-1 DNA which mostly constitutes defective and unintegrated provirus (Bruner et 
al., 2016). A study assessing the decay dynamics of integrated virus will be valuable because the 
population of cells may contain replication competent virus. Although there were a few limitations in 
our study, the integrase cell associated DNA assay used in this research project was ultrasensitive 
with a low limit of detection (3 copies per million cells), with a high success rate and reproducibility. 
As periods of poor adherence and virological failure could impact on HIV-1 decay, we only included 
31 viraemia-suppressed CHER patients in the study of associations with HIV-1 DNA which limited 
the statistical power to investigate all associations with decay. We were also not able to study the 
effect of treatment interruption in isolation as only children who started ART early were interrupted.  
Nevertheless, our study is one of very few longitudinal studies of HIV-1 DNA in children across a 
range of time points. This enabled us to investigate associates with the rate of decay and 
associations with decay over a period of ten years of antiretroviral therapy.  
4.4.2 Future considerations 
The mechanism of rapid HIV-1 DNA decay in children treated shortly after birth is not fully 
understood and requires further investigation. The proportion of HIV-1 infected cells in neonates 
with unintegrated versus integrated HIV-1 DNA is not known and the fraction of HIV-1 infected cells 
of different CD4 subsets and how that impacts on decay in early treated children is unknown. 
Assaying different subsets of CD4+ T cells in infants treated shortly after birth could provide insight 
into the lability of these immune cells and may provide insight into the mechanism of rapid decay, 
but this would remain challenging due to blood collection limits in infants. The proportion of 
proviruses that are intact or replication competent proviruses relative to defective proviruses in 
early treated infants is also not known. However, when using low HIV-1 DNA inputs, the most 
specific assay for replication competent HIV, the quantitative viral outgrowth assay (qVOA), has a 
very low yield in patients with low numbers of infected cells and its use had therefore not been 
feasible in these children. Future more sensitive molecular assays for intact proviruses may help to 
determine the true size of HIV-1 reservoirs and rate of decay of these true reservoirs. Analytical 
treatment interruption (ATI) studies are of growing importance especially with regards to studies 
investigating strategies to achieve HIV-1 remission. There is a lack of ATI studies in children. A 
comprehensive study investigating the effects of ATI on HIV-1 reservoirs (which include time to 
rebound) and immunological parameters in children would provide valuable information for the 
design of future clinical trials of curative interventions.   
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Chapter 5: Conclusion 
In line with the aims and objectives of this study we accurately quantified total HIV-1 DNA decay 
using highly sensitive and reproducible assays; and using statistical methods we were able to 
assess predictors influencing the rate of HIV-1 DNA decay. In infants who were diagnosed and 
treated very shortly after birth, we observed rapid plasma suppression, in most, and total HIV-1 
DNA became undetectable within four months of birth. We observed a faster decay rate in 
comparison to the reports of similar studies. Future research is required to accurately characterize 
the first phase of HIV-1 DNA decay in infants, but this would require the storage of PBMCs shortly 
after birth.  
In our study we also observed that children who initiated ART at around five months had a 
significantly slower decay rate than those who initiated soon after birth. Furthermore, the strongest 
predictors of slower decay were high pre-treatment HIV-1 DNA levels and increase in HIV-1 DNA 
levels over the period of therapy interruption. However, we found no lasting effect on HIV-1 DNA 
decay due to interruption, but this could be because only children who started earlier were 
interrupted. Children who had a prolonged initial treatment period had a faster decay rate. 
Interruption, as implemented in the CHER study, without virological monitoring, is no longer 
considered. Nevertheless, the absence of the long-term effects of interruption on reservoirs and 
therapy provided for a sufficient duration after initial infection, is associated with a more rapid 
decay. This may suggest that children, who were treated early and for a sufficient time, may be 
safely interrupted as part of HIV cure studies, as long as they are monitored intensively to prevent 
HIV-1 reservoir re-seeding. 
In conclusion, this study provided some of the first longitudinal data of HIV-1 DNA in children from 
a resource limited setting. We also showed that very early diagnosis and therapy initiation with 
adequate treatment adherence in the early stages of therapy may be valuable in limiting HIV-1 
persistence.  
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Addenda 
Addendum A  
Addendum A1 
A cell count was taken using a TC20™ Automated Cell Counter and the average count of live cells 
was used in the following calculations used to determine the amount of cryopreservation media 
was needed, 
                   (       ⁄ )                                     (  )                   
                 (  )                   ⁄                        
                     (  )            (  )  
             (  )             (  )      (  ) 
Addendum A2 
Calculation used to determine the amount of Guanidinium hydrochloride and Proteinase K was 
needed to prepare the GuHCl/ProK solution:  
  
   
                                            (  )  
                                (  )        (  )  
Calculation used to determine the amount of Guanidinium isothiocyanate and glycogen was 
needed to prepare the GuSCN/Gly solution: 
  
   
                                         (  ) 
                              (  )         ) 
Addendum A3 
Forward primer: 5’-CCCTACAATCCCCAAAGTCA-3’ 
Reverse primer: 5’-CACAATCATCACCTGCCATC-3’ 
Addendum A4 
Endemo DNA/RNA Copy Number Calculator (http://endmemo.com/bio/dnacopynum.php)  
This online calculator was used to calculate the exact DNA copy number by inserting your DNA 
concentration, amplicon sequence and length in base pairs. 
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Addendum A5 
CCR5 primers and probe 
Forward primer: 5’- ATGATTCCTGGGAGAGACGC-3’ 
Reverse primer: 5’- AGCCAGGACGGTCACCTT-3’ 
Probe: 5’- /56-FAM/AACACAGCC/ZEN/ACCACCCAAGTGATCA/3IABkFQ/ -3’ 
HIV-1 integrase primers and probe 
Forward primer: 5’-TTTGGAAAGGACCAGCCA-3’ 
Reverse primer: 5’- CCTGCCATCTGTTTTCCA-3’ 
Probe: 5’- /56-FAM/AAAGGTGAA/ZEN/GGGGCAGTAGTAATACA/3IABkFQ/-3’ 
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Addendum B 
Addendum B1 
 
Figure B1.1 Example of a successful qPCR experiment quantifying total HIV-1 DNA in one of the 
VEID participants. a) Amplification curve, the HIV-1 integrase standard is indicated in grey and the 
patient sample at different time points are indicated in colour. b) Standard curve of the same qPCR 
experiment which indicates an acceptable efficiency and R2  value. The standard is denoted by an 
open circle and the samples are denoted with an “x”.  
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Figure B1.2 In relation to the above figure (B1.1.) during the same qPCR experiment (VEID 
participant) CCR5 is quantified and used to measure the total number of cells being assessed. a) 
Amplification curve of the CCR5 standard (TaqMan Human genomic DNA) is indicated in grey and 
patient samples at different time points are indicated in colour. b) Standard curve of the same 
qPCR experiment which indicates an acceptable efficiency and R2 values. The standard is denoted 
by an open circle and the samples are denoted with an “x”. 
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Addendum B2 
 
Figure B2.1 Example of a successful qPCR experiment quantifying total HIV-1 DNA in one of the 
CHER/Post-CHER participants. a) Amplification curve, the HIV-1 integrase standard is indicated in 
grey and the patient sample at different time points are indicated in colour. b) Standard curve of the 
same qPCR experiment which indicates an acceptable efficiency and R2 value. The standard is 
denoted by an open circle and the samples are denoted with an “x”. 
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Figure B2.2 In relation to the above figure (B2.1) during the same qPCR experiment (CHER/Post-
CHER participant) CCR5 is quantified and used to measure the total number of cells being 
assessed. a) Amplification curve of the CCR5 standard (TaqMan Human genomic DNA) is 
indicated in grey and patient samples at different time points are indicated in colour. b) Standard 
curve of the same qPCR experiment which indicates an acceptable efficiency and R2 value. The 
standard is denoted by an open circle and the samples are denoted with an “x”. 
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“Success is not final, failure is not fatal: it is the courage to 
continue that counts.” 
Winston Churchill 
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